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A B S T R A C T
Background
Chronic wounds are common and present a health problem with significant effect on quality of life. Various pathologies may cause
tissue breakdown, including poor blood supply resulting in inadequate oxygenation of the wound bed. Hyperbaric oxygen therapy
(HBOT) has been suggested to improve oxygen supply to wounds and therefore improve their healing.
Objectives
To assess the benefits and harms of adjunctive HBOT for treating chronic ulcers of the lower limb.
Search methods
For this second update we searched the Cochrane Wounds Group Specialised Register (searched 18 February 2015); the Cochrane
Central Register of Controlled Trials (CENTRAL) (TheCochrane Library 2015, Issue 1); OvidMEDLINE (1946 to 17 February 2015);
Ovid MEDLINE (In-Process & Other Non-Indexed Citations, 17 February 2015); Ovid EMBASE (1974 to 17 February 2015); and
EBSCO CINAHL (1982 to 17 February 2015).
Selection criteria
Randomised controlled trials (RCTs) comparing the effect on chronic wound healing of therapeutic regimens which include HBOT
with those that exclude HBOT (with or without sham therapy).
Data collection and analysis
Three review authors independently evaluated the risk of bias of the relevant trials using the Cochrane methodology and extracted the
data from the included trials. We resolved any disagreement by discussion.
Main results
We included twelve trials (577 participants). Ten trials (531 participants) enrolled people with a diabetic foot ulcer: pooled data of
five trials with 205 participants showed an increase in the rate of ulcer healing (risk ratio (RR) 2.35, 95% confidence interval (CI)
1.19 to 4.62; P = 0.01) with HBOT at six weeks but this benefit was not evident at longer-term follow-up at one year. There was no
statistically significant difference in major amputation rate (pooled data of five trials with 312 participants, RR 0.36, 95% CI 0.11 to
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1.18). One trial (16 participants) considered venous ulcers and reported data at six weeks (wound size reduction) and 18 weeks (wound
size reduction and number of ulcers healed) and suggested a significant benefit of HBOT in terms of reduction in ulcer area only at six
weeks (mean difference (MD) 33.00%, 95% CI 18.97 to 47.03, P < 0.00001). We identified one trial (30 participants) which enrolled
patients with non-healing diabetic ulcers as well as venous ulcers (“mixed ulcers types”) and patients were treated for 30 days. For this
“mixed ulcers” there was a significant benefit of HBOT in terms of reduction in ulcer area at the end of treatment (30 days) (MD
61.88%, 95% CI 41.91 to 81.85, P < 0.00001). We did not identify any trials that considered arterial and pressure ulcers.
Authors’ conclusions
In people with foot ulcers due to diabetes, HBOT significantly improved the ulcers healed in the short term but not the long term and
the trials had various flaws in design and/or reporting that means we are not confident in the results. More trials are needed to properly
evaluate HBOT in people with chronic wounds; these trials must be adequately powered and designed to minimise all kinds of bias.
P L A I N L A N G U A G E S U M M A R Y
Hyperbaric oxygen therapy for treating chronic wounds
Background
Chronic wounds are wounds that take a long time to heal, do not heal, or recur; these wounds are often ulcers associated with diabetes
or arterial or venous disease (poor blood circulation). One characteristic of chronic wounds is that the wound tissues are hypoxic (have
low oxygen levels). Chronic wounds are commonly occurring and reduce the quality of life of those affected.
Hyperbaric oxygen therapy (HBOT) is a treatment designed to increase the supply of oxygen to wounds that are not responding to
other treatments. HBOT involves people breathing pure oxygen in a specially designed compression chamber (such as those used for
deep-sea divers suffering pressure problems after resurfacing).
Review question
Does hyperbaric oxygen therapy (HBOT) increase the rate of healing of people with chronic wounds and reduce the need for partial
or total lower limb amputation? Is this treatment safe?
What we found
We included twelve randomised trials (577 participants) in this updated review. Most of the included trials studied foot ulcers in people
with diabetes (10 trials).
For diabetes-related foot ulcers, we found that HBOT seemed to improve the chance of healing in the short term (up to six weeks),
but not with longer term follow-up. HBOT may reduce the number of major amputations in people with diabetes who have chronic
foot ulcers.
For chronic wounds caused by disease to the veins of the leg, we found that HBOT may reduce the size of wounds.
For chronic wounds caused by lack of blood supply through the arteries or chronic pressure ulcers, we found no evidence to confirm
or refute any effects of HBOT.
We could not assess safety as none of the trials included in our review reported whether there were any major adverse events.
This plain language summary is up-to-date as of 23/1/15
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hyperbaric Oxygen Therapy for chronic wounds
Patient or population: patients with chronic wounds
Settings: inpatients and outpatients in a hyperbaric facility
Intervention: Hyperbaric Oxygen Therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Hyperbaric Oxygen
Therapy
Diabetic ulcers healed at
1 year.
Follow-up: 1 years
Study population RR 9.53
(0.44 to 207.76)
212
(3 studies)
⊕⊕⊕©
moderate1,2,3
115 per 1000 1000 per 1000
(51 to 1000)
Low
0 per 1000 0 per 1000
(0 to 0)
High
0 per 1000 0 per 1000
(0 to 0)
Diabetic ulcers - major
amputations
Study population RR 0.36
(0.11 to 1.18)
312
(5 studies)
⊕⊕⊕©
moderate2
247 per 1000 89 per 1000
(27 to 284)
Low
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0 per 1000 0 per 1000
(0 to 0)
High
0 per 1000 0 per 1000
(0 to 0)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Analysis comprises small studies, some with zero events in control arm
2 small sample size
3 very large effect: RR >5
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B A C K G R O U N D
Description of the condition
A chronic wound is any interruption in the continuity of the body’s
surface that requires a prolonged time to heal, does not heal, or re-
curs (Wysocki 1996). For the purpose of this review we have gen-
erally defined ’chronic’ as those wounds where attempts to heal by
means other than hyperbaric oxygen therapy have failed. Chronic
wounds arise in a great variety of situations and may be associated
with a number of pathological processes. In order to institute ap-
propriate therapy, it is common practice to define such wounds
by their most likely aetiology. Thus, wounds developing in the
presence of demonstrated arterial insufficiency would be termed
’arterial ulcers’ and therapeutic measures would aim to improve is-
chaemia in the limb in order to promote healing, perhaps through
bypass surgery when technically possible (Fowkes 2008). In ulcers
associated with venous insufficiency, on the other hand, compres-
sion bandaging is likely to be more appropriate (O’Meara 2009;
Escaleira 2010). The most common chronic wounds encountered
in western medical practice are a consequence of diabetes, arterial
and/or venous disease, sustained pressure, and those as a result of
therapeutic irradiation for the treatment of tumours. More than
one such process may be present in an individual and contribute
to the wound and they are more common in the elderly and those
with multiple health problems (Dealey 1994; Lauterbach 2010).
Chronic wounds are common and constitute a significant health
problem. The true incidence and impact are difficult to assess ac-
curately given the wide range of disease, the fact that much care
is delivered at home and that many wound care products are pur-
chased directly in some countries. While most leg ulcers will be
the result of venous insufficiency, about 25% are likely to be ar-
terial (Andersson 1993; O’Meara 2009). Wound care in the UK
costs in excess of GBP 1 billion per year and therefore treatment
options that are both clinically effective and cost-effective are vital
(Banwell 1999). The availability of a great variety of treatment op-
tions for chronic wounds is a consequence of the range of different
aetiologies. However, there is also a possibility that many of the
treatment options are ineffective. By definition, chronic wounds
are indolent or progressive and resistant to the wide array of treat-
ments applied. There is a plethora of wound care products avail-
able - many at considerable cost. In some areas, dedicated wound
care teams have been developed in an attempt to maximise suc-
cessful healing and contain costs through improved efficiency.
Wound management techniques are continuously being devel-
oped. Strategies include treatment of the underlying pathology
(e.g. optimal diabetes carewith blood glucose control, vein surgery,
arterial reconstruction), systemic treatment aimed at improving
the local wound environment (e.g. nutrition supplements, pen-
toxifylline, aspirin, flavonoids, thromboxane alpha-2 agonists, su-
lodexide) (Langer 2003; Palfreyman 2006; Jull 2007) and local
treatment aimed at improving the wound environment (e.g. dress-
ings, negative local pressure, pressure-relieving mattresses, ultra-
sound, application of growth factors, skin-grafting) (Jull 2008;
Ubbink 2008; Akbari Sari 2009; Jones 2009; Cullum 2010;
Edwards 2010; Aziz 2011; Dumville 2011a; Dumville 2011b).
There are many others. In practice, wound management is often
a sequential search for a successful combined approach.
Wound types
Diabetic foot ulcer
One particular type of chronic wound often associated with is-
chaemia is the foot ulcer associated with diabetes. It has been esti-
mated that 2% of the UK population have diabetes, of whom up
to 25% experience foot ulceration and in whom the amputation
rate is 15 to 70 times that in the general population (SIGN 1997;
Calman 1998; Singh 2005). In diabetes mellitus, the development
of foot ulcers is usually the result of peripheral neuropathy and/
or peripheral vascular disease. The annual incidence of foot ul-
cers among people with diabetes has been variously estimated a
between 2.5% to 10.7%, and the annual incidence of amputation
is 0.25% to 1.8% (Apelqvist 1993; Lee 1993; Humphrey 1996;
Boulton 2008). Ulcer care is responsible for a large proportion
of the cost of health care for people with diabetes. The relapse
rate for diabetic foot ulcers is 66% over five years. Approximately
12% of people with ulcers progress to lower extremity amputation
(Apelqvist 1993).
Venous ulcer
Venous ulcers (also known as varicose or stasis ulcers) are caused
by venous reflux or obstruction resulting in high venous pressure.
Estimates for the prevalence of leg ulcers range between 1.5 and
3 per 1000 population, and 1% to 2% of people will have a ve-
nous ulcer at least once during their life (Amsler 2009). The rate
increases with age to about 20 per 1000 people aged over 80 years
(Callam 1985). It has been estimated that in the UK, the cost to
the NHS of treatment for venous ulcers alone may be GBP 300 to
450 million annually (Bosanquet 1992), and that district nurses
devote between 25% and 50% of their time to the care of people
with ulcers (Lees 1992).
Arterial ulcer
Arterial ulcers are the result of impaired perfusion to the feet or
legs and are viewed as one clinical sign of general arteriosclerosis.
Intermittent claudication may accompany this disease and can be
usually found at earlier stages of the arteriosclerosis, while skin
lesions or even necrosis represent an end stage of the peripheral
manifestation of general arteriosclerosis.
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Pressure ulcer
Pressure ulcers (also known as pressure sores, decubitus ulcers and
bed sores) may present as broken or necrotic skin, most often
extending to the underlying tissue, including muscles and bone.
They are caused by unrelieved pressure or friction and can be
found predominantly below the waist and at bony prominences
(sacrum, heels, hips). Increased age, reduced mobility and mal-
nutrition constitute relevant risk factors, however, their respective
impact on the genesis of ulcers remains unknown (Allman 1997;
Reddy 2008). Pressure ulcers can be viewed as typical complica-
tions in all healthcare settings with a prevalence of 6% to 10% in
National Health Services hospitals in the UK (O’Dea 1999)
Description of the intervention
Hyperbaric oxygen therapy (HBOT) is a treatment modality that
has been used in chronic wounds for about 40 years (Kulonen
1968). It is relatively widely available in North America (where
there are more than 300 facilities registered with the Undersea
and Hyperbaric Medical Society (UHMS)), Russia, China and
Cuba, but less well-established in Europe and Australasia (UHMS
2001a). Treatment involves placing the patient in a compression
chamber, increasing the environmental pressure within the cham-
ber, and administering 100% oxygen for respiration. In this way,
it is possible to deliver a greatly increased partial pressure of oxy-
gen to the tissues. Typically, treatments involve pressurisation to
between 2.0 and 2.5 atmospheres absolute (ATA) for periods be-
tween 60 and 120 minutes once or twice daily. A typical course
might involve 15 to 30 such treatments.
How the intervention might work
The rationale forHBOT is that, despite the wide range of causative
pathologies, the common denominator in many wounds is tissue
hypoxia. Wound healing is a complex and incompletely under-
stood process. While it appears that in acute wounds healing is
enabled by the initial hypoxia, low pH and high lactate concen-
trations found in freshly injured tissue (Knighton 1983; Jensen
1986), some elements of tissue repair are extremely oxygen-de-
pendent, for example collagen elaboration and deposition by fi-
broblasts (Hunt 1972; Niinikoski 1972a) and bacterial killing by
macrophages (Hohn 1976). In a complicated balance between
wound hypoxia and peri-wound oxygenation, it would seem that
successful healing relies on adequate tissue oxygenation in the area
surrounding the fresh wound. Certainly, wounds that lie in hy-
poxic tissue beds are those that most often display poor or absent
healing (Niinikoski 1972b; Sheffield 1985).
Some causes of tissue hypoxia will be reversible with HBOT, while
some will not. One very common cause for peripheral tissue hy-
poxia is ischaemia due to large vessel disease. In this situation, al-
though the administration of HBOT will result in very high ar-
terial partial pressures of oxygen, this oxygen will not reach the
woundbeddue to inadequate perfusion. In other clinical situations
the cause of tissue hypoxia may be small vessel disease or oedema,
and may be overcome by a high driving pressure of oxygen in
the arterial blood. This has been demonstrated in hypoxic tissues
where regional perfusion is reasonably preserved, through the use
of transcutaneous and implantable oxygen electrodes (Sheffield
1985). In wound healing, insufficient supply of oxygen may pre-
vent normal healing processes. The intermittent presentation of
oxygen to those hypoxic tissues, therefore, may allow a resump-
tion of normal healing. HBOT administration in man has been
demonstrated to cause hyper-oxygenation of tissue, vasoconstric-
tion, fibroblast activation, down-regulation of inflammatory cy-
tokines, up-regulation of growth factors, antibacterial effects, po-
tentiation of antibiotics, and a reduction in leukocyte chemotaxis
(Sheffield 1985; Rabkin 1988; Cianci 1993; Stevens 1993; Zhao
1994; Bayati 1998; Dimitrijevich 1999).
Oxygen in high doses is toxic to normally perfused tissue, in par-
ticular the brain and lungs. Therefore it is not possible to expose
patients to typical wound treatment pressures for longer than one
to two hours on a regular basis and the question arises as to how
such short exposures could be expected to result in a clinical ben-
efit. There are two principal reasons why this might be so. First,
elevation of wound oxygen tension may persist for some hours
following HBOT and so exert therapeutic effects for rather longer
than might be expected (Siddiqui 1997). Second, there is exper-
imental evidence that repeated ’on-off ’ exposures do produce an
environment favourable to healing when compared to oxygen or
air at normobaric pressure. In a rabbit model where wounds were
produced by irradiation to the lower face, Marx 1990 assessed the
angiogenic properties of normobaric oxygen (100% oxygen at 1
ATA for 90 minutes daily) and hyperbaric oxygen (100% oxygen
at 2.4 ATA for 90 minutes daily for 20 days), as compared with
air-breathing controls. Results indicated that normobaric oxygen
had no angiogenic properties above the normal revascularisation
of irradiated tissue than air-breathing controls (P = 0.89). Hyper-
baric oxygen demonstrated an eight- to nine-fold increased vascu-
lar density over both normobaric oxygen and air-breathing con-
trols (P = 0.001).
Why it is important to do this review
HBOT is always presented as an adjunctive therapy to normal
wound caremeasures, and is not proposed as an alternative therapy
capable of inducing healing in the absence of good wound care
(UHMS 2001). Using both clinical assessment and investigations
designed to confirm significant peri-wound hypoxia, hyperbaric
practitioners attempt to select those wounds where a response to
HBOT is considered likely. Often this decision is based on tran-
scutaneous oxygen measurements of the peri-wound area, both
while air-breathing at normal pressure and on administration of
hyperbaric oxygen. If HBOT can be shown to have a beneficial
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effect on wound healing, then we hypothesise that the addition of
this treatment modality may improve the proportion of wounds
that achieve healing and thereby enhance the quality of life in such
selected participants. One review suggests the addition of HBOT
may reduce the overall costs associated with the treatment of dia-
betic ulcers (Chuck 2008).
HBOT is associated with some risk of adverse effects including
damage to the ears, sinuses and lungs from the effects of pres-
sure, temporary worsening of short-sightedness, claustrophobia
and oxygen poisoning (Clarke 2003). Although serious adverse
events are rare,HBOTcannot be regarded as an entirely benign in-
tervention. Furthermore, as an adjunct to standard therapyHBOT
may be associatedwith increased costs, and any cost/benefit advan-
tage should be carefully assessed. The administration ofHBOT for
people with chronic wounds remains controversial. While much
of the justification derives from pathophysiology and anecdote,
there have been a number of attempts to demonstrate a beneficial
effect in formal clinical trials in a variety of disease states. In this
review we have limited our interest to those chronic wounds asso-
ciated with diabetes mellitus, peripheral arterial and venous dis-
ease and pressure-related ulcers. The treatment of wounds related
to therapeutic irradiation will be the subject of a separate review.
O B J E C T I V E S
The aim of this review was to assess the evidence for the benefit of
hyperbaric oxygen treatment (HBOT) for the treatment of chronic
wounds. Does HBOT:
• increase the rate of healing of diabetic foot ulcers?
• increase the rate of healing of venous leg ulcers?
• increase the rate of healing of arterial ulcers of the lower
limb?
• increase the rate of healing of pressure ulcers?
• reduce the proportion of people with diabetic foot ulcers
who undergo partial or total amputation of the lower limb?
• reduce the proportion of people with arterial ulcers of the
lower limb who undergo partial or total amputation of the lower
limb?
Is HBOT safe in the short and long term?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) that compare the effect on
chronic wound healing of treatment with HBOT compared with
no HBOT.
Types of participants
Any person in any healthcare setting with a chronic wound asso-
ciated with venous or arterial disease, diabetes mellitus or external
pressure. We defined chronic wounds as described in the retrieved
papers (prolonged healing or healing by secondary intention), but
there must have been some attempt at treatment by other means
prior to the application of HBOT.
Types of interventions
Wound care regimens which includedHBOT compared with sim-
ilar regimens that excluded HBOT. Where co-interventions dif-
fered significantly between trials we clearly stated this and dis-
cussed the implications.
HBOT administered in a compression chamber between pressures
of 1.5 ATA and 3.0 ATA and treatment times between 30 minutes
and 120 minutes daily or twice daily. The comparator group was
diverse; we accepted any standard treatment regimen designed to
promote wound healing. The salient feature of the comparison
group was that these measures had failed before enrolment in the
trials. We planned subgroup analysis to evaluate the impact of
different comparator strategies.
Types of outcome measures
Primary outcomes
Diabetic ulcers:
• proportion of ulcers healed;
• proportion of people undergoing major amputation
(defined as amputation of the lower or upper extremity above the
ankle or the wrist, respectively).
Venous ulcers:
• proportion of ulcers healed.
Pressure ulcers:
• proportion of ulcers healed.
Mixed ulcers group:
• proportion of ulcers healed.
• proportion of people undergoing major amputation
(defined as amputation of the lower or upper extremity above the
ankle or the wrist, respectively).
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Secondary outcomes
Diabetic ulcers:
• time to complete healing;
• wound size reduction;
• proportion undergoing minor amputation (defined as
amputation of a hand or foot or any parts of either);
• quality of life;
• transcutaneous oxygen tensions and recurrence rate.
Venous ulcers:
• time to complete healing;
• wound size reduction;
• quality of life;
• pain;
• recurrence rate.
Pressure ulcers:
• time to complete healing;
• wound size reduction;
• quality of life;
• recurrence rate.
Mixed ulcers group:
• time to complete healing;
• wound size reduction;
• proportion undergoing minor amputation (defined as
amputation of a hand or foot or any parts of either);
• quality of life;
• transcutaneous oxygen tensions and recurrence rate.
Adverse events of HBOT:
• proportion of people with visual disturbance (short and
long-term);
• barotrauma (aural, sinus, pulmonary in the short and long-
term);
• oxygen toxicity (short-term) with respect to HBOT
obtained from the included trials;
• any other adverse events.
We also examined the proportion of people withdrawn from treat-
ment for any reason and planned to relate such withdrawals to the
frequency and dose of HBOT where possible.
Search methods for identification of studies
The search methods section of the original version of this review
can be found in Appendix 1.
Electronic searches
For this second update we searched the following electronic
databases:
• The Cochrane Wounds Group Specialised Register
(searched 18 February 2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2015, Issue 1);
• Ovid MEDLINE (1946 to 17 February 2015);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, 17 February 2015);
• Ovid EMBASE (1974 to 17 February 2015);
• EBSCO CINAHL (1982 to 17 February 2015).
We used the following search strategy in the Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor: [Chronic Disease] explode all trees 10595
#2 MeSH descriptor: [Wound Healing] explode all trees 4098
#3 #1 and #2 280
#4 MeSH descriptor: [Skin Ulcer] explode all trees 1720
#5 MeSH descriptor: [Diabetic Foot] explode all trees 433
#6 (skin next ulcer*) or (foot next ulcer*) or (diabetic next (foot
or feet)) or (leg next ulcer*) or (varicose next ulcer*) or (venous
next ulcer*) or (stasis next ulcer*) or (arterial next ulcer*) 2790
#7 ((ischaemic or ischemic) next (wound* or ulcer*)) 88
#8 (bed next sore*) or (pressure next sore*) or (pressure next ulcer*)
or (decubitus next ulcer*) 1174
#9 (chronic next wound*) 292
#10 (chronic near ulcer*) 1099
#11 #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 4559
#12MeSH descriptor: [Hyperbaric Oxygenation] explode all trees
358
#13 hyperbar* next oxygen* 751
#14 high next pressure next oxygen* 18
#15 oxygen*:ti 4393
#16 #12 or #13 or #14 or #15 4549
#17 #11 and #16 113
The search strategies for Ovid MEDLINE, Ovid EMBASE and
EBSCO CINAHL can be found in Appendix 2; Appendix 3
and Appendix 4 respectively. We combined the Ovid MEDLINE
search with the Cochrane Highly Sensitive Search Strategy for
identifying randomised trials in MEDLINE: sensitivity- and pre-
cision-maximising version (2008 revision) (Lefebvre 2011). We
combined the Ovid EMBASE and EBSCO CINAHL searches
with the trial filters developed by the Scottish Intercollegiate
Guidelines Network (SIGN) (SIGN 2011). There were no restric-
tions with respect to language, date of publication or trial setting.
We contacted authors to discuss any ambiguity about the pub-
lished data.
Searching other resources
We searched the bibliographies of all retrieved and relevant pub-
lications to identify any further eligible trials.
Data collection and analysis
Selection of studies
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For the original version of the review, one review author (MB) was
responsible for handsearching and identifying appropriate trials
for consideration. Three review authors (PK, MB and IR) inde-
pendently examined the electronic search results and identified
potentially relevant trials. We retrieved all comparative clinical tri-
als identified and judged to be potentially relevant in full and three
review authors reviewed them independently, two with content
expertise in the treatment of chronic wounds with HBOT, one
with content expertise in treating chronic woundswithoutHBOT.
In addition, two of the review authors (MB, IR) have expertise in
clinical epidemiology. For the review update, four review authors
made trial selection decisions (SW, MB, MMSJ, and AS).
Data extraction and management
Using the data extraction form developed for this review, each re-
view author extracted relevant data and made a recommendation
for inclusion or exclusion in this review based on an appraisal of
the trial methodology. The number of participants originally allo-
cated to the HBOT and control groups was extracted to allow an
’intention-to-treat analysis’ (ITT) approach in the meta-analysis
(see Dealing with missing data and Data synthesis). We identified
losses to follow-up where this information was reported.
For the update, MB and SW undertook data extraction and this
was checked by PK. We settled any differences by consensus. The
data extracted included the following.
1. Trial authors
2. Year of publication
3. Study design (RCT)
4. Inclusion criteria for participants
5. Baseline characteristics of participants
6. Numbers recruited and allocated
7. Method of randomisation
8. Method of participant allocation
9. Blinding of participants and trial personnel
10. Details of the intervention (treatment and comparator)
11. Setting of treatment
12. Duration of intervention/follow-up periods
13. Outcomes measured
14. Number of participants completing
15. Reporting of withdrawals
16. Reasons for participant withdrawal
17. Statistical methods used in the analysis
18. Methods for handling missing data (per-protocol or ITT
analysis)
19. Results per group for each outcome
20. Adverse events
Assessment of risk of bias in included studies
We appraised each included trial to assess the risk of bias as out-
lined in section 8.5 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011) and according to the criteria
described below. ’Unclear risk’means that insufficient information
was available to make a judgement.
1. Random sequence generation (selection bias)
Low risk: adequate sequence generation was reported using ran-
dom number tables, computer random number generator, coin
tossing or card/envelope shuffling.
High risk: used a system involving dates, names or admittance
numbers for the allocation of participants. We considered such
trials as quasi-randomised and excluded them from the review.
Unclear risk: did not describe one of the adequate methods but
mentioned randomisation.
2. Allocation concealment (selection bias)
Low risk: a randomisation method was described that would not
allow an investigator/participant to know or influence allocation
to an intervention group before an eligible participant entered the
trial, such as central randomisation or serially numbered, opaque,
sealed envelopes.
High risk: an inadequate method of allocation was used, such as
alternate medical record numbers or unsealed envelopes; or there
was information in the trial report indicating that investigators or
participants could have influenced group allocation.
Unclear risk: the trial report mentioned randomisation but there
was no information on themethod used, or amethodwas reported
that was not clearly adequate.
3. Blinding of participants (performance bias and
detection bias)
Wegraded this item as ’low risk’ for blinding participants, ’unclear’
if the relevant information was not stated in the trial report and
’high risk’ for unblinded participants.
4. Blinding of outcome assessors (performance bias
and detection bias)
We graded this item as ’low risk’ for blinded outcome assessment,
’unclear’ if the relevant information was not stated in the trial re-
port and ’high risk’ for any statement indicating unblinded out-
come assessment.
5. Incomplete outcome data addressed (description
of withdrawals)
Low risk: numbers of withdrawals per group with reasons pro-
vided; or clear from report that there were no withdrawals.
High risk: some withdrawal evident but numbers per group and
reasons not provided.
Unclear risk: unclear from trial report whether there were any
withdrawals.
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6. Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
We defined ITT analysis as being conducted when all trial partic-
ipants were analysed in the group to which they were randomised
regardless of which (or how much) of the treatment they actually
received, and regardless of other protocol irregularities, such as
ineligibility.
Low risk: trial report stated that ITT was undertaken and this was
confirmed on trial assessment, or not stated but evident from trial
assessment that ITT was undertaken.
High risk: ITT not confirmed on trial assessment (participants
who were randomised were not included in the analysis because
they did not receive the trial intervention, they withdrew from the
trial or were not included because of protocol violation) regardless
of whether analysis described as ITT.
Unclear risk: described as ITT analysis, but unable to confirm on
trial assessment, or not reported and unable to confirm by trial
assessment.
7. Selective reporting
We defined selective reporting as whether all outcomes detailed in
an original trial protocol were presented in the published report
as follows:
Low risk: all outcomes in trial protocol are reported.
High risk: only certain outcomes from the original protocol (for
example outcomes with a statistically significant beneficial effect)
are reported
Unclear risk: full trial protocol not available (from trial investiga-
tors or a trials register).
In the absence of the availability of a full trial protocol for any
included report, we noted whether the results section of the pub-
lished report presented results for all outcomes that were described
in the methods section.
Measures of treatment effect
Dichotomous data
For the dichotomous outcomes we presented the summary esti-
mate as a risk ratio (RR) with 95% confidence intervals (CI). We
estimated the RR using the intention-to-treat (ITT) data of the
treatment group (HBOT) compared with the ITT of the control
group. The dichotomous outcomes included the following.
1. Wounds healed
2. Major amputations
3. Minor amputations
4. Ulcer recurrence
5. Adverse events
In the original review we presented a RR of failing to heal. For
this update, we presented the RR of healing in order to facilitate
ease of interpretation for the reader of the healing outcomes. The
interpretation of the RR was that a summary estimate in which
HBOTincreased the occurrence of healingwould have aRR>1.00
and a summary estimate in which HBOT reduced the occurrence
of amputation, ulcer recurrence or adverse events would have a
RR < 1.00.
For the dichotomous outcomes, we analysed the number of re-
ported events in each arm against the number of participants orig-
inally randomised to that arm at trial enrolment (ITT). We then
undertook sensitivity analyses to include people (events) poten-
tially lost to follow-up (see Dealing with missing data).
Continuous data
Where continuous outcomesweremeasured in the sameway across
trials, we presented a mean difference (MD) with 95% CI. We
presented a standardised mean difference (SMD) where trials mea-
sured the same outcome using different methods. The continuous
outcomes included the following.
1. Time to complete healing
2. Ulcer size reduction
3. Quality of life
4. Transcutaneous oxygen tension
5. Pain
Dealing with missing data
For the trials indicating missing data as participants allocated for
whom no outcome data were presented, we adopted the ‘best-
case’ and ‘worst-case’ scenario method cited in section 16.2 in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). The ‘best-case’ scenario is that all participants with miss-
ing outcomes in the experimental intervention group had good
outcomes, and all those with missing outcomes in the control in-
tervention group had poor outcomes. The ‘worst-case’ scenario is
the converse.
Data synthesis
We undertook statistical pooling using Cochrane RevMan soft-
ware (version 5.3) (RevMan 2014). We assessed statistical be-
tween-trial heterogeneity using the I2 statistic (Higgins 2011).We
applied a fixed-effect model where trials examined the same in-
terventions, the populations and methods described were suffi-
ciently similar, and low levels of between-trial heterogeneity were
evident (I2 ≤ 30%, Higgins 2011). If statistical heterogeneity was
detected, we used a random-effects model to produce an overall
summary estimate. As an estimate of the clinical relevance of any
difference between experimental intervention and control inter-
vention we calculated the number needed to treat (NNT) with
95% CI as appropriate. We undertook and presented a narrative
synthesis of all trials.
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Subgroup analysis and investigation of heterogeneity
Since the obtained NNTs or numbers needed to harm (NNHs)
differ depending on the underlying risk for an event in the trial
population,we considered subgroup analyses due to different base-
line risks, in which case we planned to use ’truncated’ data restrict-
ing the analyses to a predefined control event rate.
Where appropriate data were available, we also considered sub-
group analysis based on the following.
1. Wound entry grade or severity using established wound
classification systems where the authors have employed those
systems.
2. Dose of oxygen received (pressure, time and length of
treatment course).
3. Nature of the comparative treatment modalities.
Sensitivity analysis
We undertook sensitivity analysis for the effects of missing data,
employing the best-case and worse-case scenarios as described
above.
R E S U L T S
Description of studies
Results of the search
In our original report, we identified 26 publications dealing with
the treatment of chronic wounds with adjunctive HBOT and for
the first update we identified a further 25 publications, for the
second update we identified a further 24 publications. Initial ex-
amination suggested 31 possible comparative trials where systemic
hyperbaric oxygen was employed in at least one arm of the trial.
After appraisal of the full report for these trials, we excluded 18
publications. Twelve trials met the inclusion criteria for the review.
We identified two published protocols to ongoing trials and added
those to Characteristics of ongoing studies for consideration in a
subsequent update (O’Reilly 2011; Stoekenbroek 2015).
Included studies
In total, twelve trials contributed to this review and these were
published between 1992 (Doctor 1992) and 2014 (Ma 2013). In
total, these trials include data on 577 participants, 281 receiving
HBOT and 267 receiving control or comparator treatment, and
the largest (Duzgun 2008) accounts for 17%of participants. In the
reports of Doctor 1992 and Lin 2001, the number of participants
randomised to each arm was not specified, and we were unable
to obtain this information through contact with the authors. We
have assumed an equal distribution for this review. One of the
trials included patients with venous ulcers (Hammarlund 1994),
and one trial included a mixed group of patients with diabetic and
venous ulcers (Kaur 2012), while the other ten included people
with diabetic ulcers (See Characteristics of included studies).
Diabetic foot ulcers
Ten trials comparing HBOT with control (either with or without
sham) enrolling a total of 531 people with diabetic ulcers were in-
cluded in this analysis (Abidia 2003; Doctor 1992; Duzgun 2008;
Faglia 1996a; Kessler 2003; Lin 2001; Londahl 2010; Khandelwal
2013; Ma 2013; Wang 2011). The treatment pressure and time
schedule used for delivery of oxygen varied between trials. Doctor
1992 used 3.0 ATA for 45 minutes, while the remainder used be-
tween 2.2 and 2.5 ATA for between 60 and 120 minutes. Nine
trials gave between 20 and 40 sessions once or twice daily either
five or six days each week, whilst one trial (Doctor 1992) un-
usually applied four sessions only, over a period of two weeks.
Three trials (Abidia 2003; Lin 2001; Londahl 2010) employed
a sham treatment in the control group, on the same schedule as
the HBOT group. The other seven trials did not employ a sham
therapy (Doctor 1992; Faglia 1996a; Kessler 2003; Duzgun 2008;
Khandelwal 2013; Ma 2013; Wang 2011).
Inclusion criteria varied in these trials. Doctor 1992 included any
personwith diabeteswith a chronic foot lesion (time not specified);
Faglia 1996a included people with diabetes and Wagner grade 2,
3 or 4 lesions (Wagner 1987); Lin 2001 and Kessler 2003 people
with “early diabetic feet”, Wagner grades 0, 1 or 2, while Duzgun
2008; Abidia 2003 and Londahl 2010 included people with dia-
betes whose lesions had been present for more than four weeks, six
weeks and three months respectively. In addition, Londahl 2010
required evidence of good standardwound care in a specialist clinic
setting for a minimum of two months. Exclusion criteria generally
followed from the specific inclusions detailed above, but Abidia
2003 also specifically excluded participants for whom vascular sur-
gical procedures were planned and Kessler 2003 excluded all pa-
tients with transcutaneous oxygen tensions of < 30 mmHg. Ma
2013 included patients with diagnosed diabetes, at least one full-
thickness wound below the ankle (Wagner grades III or less) for
> 3 month, standard care for > 2 month, TcPO2 > 30 mmHg.
Khandelwal 2013 included patients with a diabetic foot ulcer of at
least 8 weeks duration, patients with only stage III and IV diabetic
foot ulcer and the absence of vascular insufficiency.
Overall sample size ranged from 18 participants (Abidia 2003) to
100 participants (Duzgun 2008). Only one trial reported under-
taking a sample size calculation, which was for amputation rate
(34 in each arm, Faglia 1996a). There is a possibility that some
of the included trials may have been underpowered to detect a
statistically significant effect of HBOT on healing or amputation
rates.Where baseline ulcer size and durationwere reported (Abidia
2003; Kessler 2003; Londahl 2010), there were no between-group
imbalances evident from the published report.
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Given the different centres involved, the comparator treatment
was unlikely to have been exactly the same in any of the trials. One
trial did not specify any comparator (Lin 2001). Sixtrials described
a comprehensive and specialised multidisciplinary wound man-
agement programme to which HBOT was added for the active
arm of the trial (Faglia 1996a; Abidia 2003; Kessler 2003; Duzgun
2008; Londahl 2010; Ma 2013), and one specified a surgical and
dressing regimen common to both arms (Doctor 1992).
The follow-up periods varied between trials. Two trials reported
data immediately following the course of therapy (Lin 2001; Ma
2013), two trials followed patients to discharge from hospital (
Doctor 1992; Faglia 1996a), one followed patients for two weeks
after therapy (Kessler 2003), one followed patients for ten weeks
or till the ulcers healed (Khandelwal 2013), two gave results at one
year (Abidia 2003; Londahl 2010) and one trial followed patients
for 22 months (Duzgun 2008). All included trials reported at
least one outcome of interest. Other outcomes reported included
positive wound cultures (Doctor 1992), number of outpatient
visits and cost of wound dressings over one year (Abidia 2003),
vascular responsiveness (Abidia 2003), transcutaneous oximetry
(Kessler 2003) and laser-Doppler perfusion scans (Lin 2001).
One trial (86 people) compared HBOT to extracorporeal shock-
wave therapy (ESWT) in a head-to-head manner (Wang 2011).
Inclusion criteria were people with chronic non-healing diabetic
foot ulcers of greater than three months duration. HBOT was de-
livered at ATA 2.5 for 90 minutes, five days per week up to 20
treatments. The trial reported the proportion of ulcers healed at
the end of treatment, laser-Doppler perfusion, and cell prolifera-
tion and apoptosis.
Venous ulcers
Hammarlund 1994 used a treatment session of 2.4 ATA for 90
minutes to a total of 30 sessions over six weeks, and employed
an air-breathing sham treatment on the same schedule. The trial
recruited 16 participants who were required to have persistent
venous ulcers for more than one year with arterial blood pressures
at the ankle and great toe within the normal range when compared
with upper limb pressure. The ulcers were matched in pairs by size
during the randomisation process, and mean wound areas were
similar at the time of entry into the trial. Participantswere excluded
if they were currently smoking or had chronic illnesses such as
diabetes or connective tissue disorders. The recruitment period for
this trial is not known, but was over one year. The comparator
treatment was not specified. Participants were followed up to 18
weeks from enrolment and data were obtained on wound area
and the presence or absence of complete healing. The trial did
not report undertaking a sample size calculation and may have
been underpowered to detect any statistically significant effect of
treatment.
Mixed ulcers group
Kaur 2012 included 30 consenting patients with nonhealing ul-
cers, despite conventional therapy of more than 4 weeks duration
and different comorbidities (diabetes, hypertension, varicose vein,
vascular insufficiency).The patients were randomized into either
the control group (receiving only conventional treatment) or the
HBOT group (receiving conventional treatment in addition to
HBOT;HBOTwas delivered at 2.5ATA for 90min, 6days aweek,
a total of 30 sessions). The different comorbidities were equally
distributed between the experimental and the control group (5 x
Diabetes mellitus, 6 x hypertension, 2 x varicose vein, 2 x vascular
insufficiency). The study report a sample size calculation for the
primary outcome “wound size reduction”. Participants were fol-
lowed until the end of the treatment (30 days).
Excluded studies
We excluded 17 trials: six where allocation was not random
(Holbach 1978; Baroni 1987; Oriani 1990; Zamboni 1997;
Kalani 2000; Kalani 2002), two where the intervention of inter-
est was topically applied oxygen (Heng 1984; Heng 2000), three
where all participants received HBOT (Deng 2006; Efrati 2009;
Kaya 2009), one dealing with acute burn wounds (Perrins 1967),
one dealing with pelviperineal necrotising infections Cruz 2003,
one which was an animal study (Whelan 2001) and one which was
a study protocol with no further information available (Mathieu
2011). Three of the remaining reports were excluded as contribut-
ing no appropriate outcome data. (Faglia 1996b; Chin 2001) and
an approach to contact the authors did not produce further data
(see Characteristics of excluded studies).
Risk of bias in included studies
Weestimated the risk of bias in each of these trials using the ’Risk of
bias’ tables and the assessments have been graphically represented
in Figure 1.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Random sequence generation
Five trials (Faglia 1996a; Kessler 2003; Duzgun 2008; Kaur 2012;
Ma 2013) described using random number tables to generate the
randomisation sequence and we deemed them to be at low risk of
bias for this domain. All of the other included trials did not report
how the randomisation sequence was generated and we classified
them as at unclear risk of bias.
Allocation concealment
Information that the allocation process was concealed was pro-
vided by the trial author for one trial (Lin 2001).We classified this
trial as being at low risk of bias for this domain. Two trials reported
using sealed envelopes but did not report that the envelopes were
sequentially numbered and opaque (Abidia 2003; Londahl 2010).
We classified these and all other included trials as at unclear risk
of bias.
Blinding
Blinding of participants and personnel
Participants were blind to treatment group allocation in three trials
(Hammarlund 1994; Abidia 2003; Londahl 2010) and we there-
fore classified them as low risk of bias. One trial reported that par-
ticipants were not blinded and we classified it as high risk (Wang
2011). One trial does not specify the treatment of the control arm
and we assessed this study as unclear risk of bias (Lin 2001). All
other trials did not offer a sham treatment to the control arm and
we therefore classified them as high risk of bias (Doctor 1992;
Duzgun 2008; Faglia 1996a; Kaur 2012; Khandelwal 2013; Ma
2013).
Blinding of outcome assessment
Statements that outcome assessors were blind to participant group
allocation were reported in three trials that we classified as low
risk of bias for this domain (Abidia 2003; Kessler 2003; Londahl
2010). All other included trials did not provide any statement
regarding blinding of the outcome assessment and we classified
them as at unclear risk of bias.
Incomplete outcome data
Incomplete outcome data reported
The number of participants withdrawing/excluded from each
treatment arm, along with reasons, was reported in thee trials
(Faglia 1996a; Londahl 2010; Wang 2011). Londahl 2010 re-
ported both an intention-to-treat (using all enrolled participants)
and a ’per-protocol’ analysis of those receiving at least 35 treatment
sessions (11 participants allocated to HBOT and eight to sham).
In the other trials there were no withdrawals or loss to follow-up
that appeared in the analysis in any of the trials. One trial reported
that all participants completed treatment (Hammarlund 1994).
We classified these trials as low risk. One trial (Khandelwal 2013)
reported numbers of lost participants during follow-up, however,
without reporting reasons for withdrawal. Therefore, we classified
this trial as high risk of bias.All of the other included trials did
not provide a statement regarding attrition and we classified them
as unclear risk. The numbers of participants lost to final follow-
up are summarised in Table 1. Overall, there were 49 participants
lost to final follow-up (8.5% of the total number enrolled).
Incomplete outcome data addressed
We classified one trial reporting that all recruited participants com-
pleted the intervention (Hammarlund 1994) as at low risk of bias.
One trial reporting attrition of 22% in the HBOT arm presented
both a per-protocol (> 35 treatment sessions) and an intention-
to-treat analysis (Londahl 2010). We also classified this trial as
being at low risk of bias. One trial reported an intention-to-treat
design, but excluded participants who withdrew from the final
analysis (Abidia 2003), and two trials indicated that some par-
ticipants who were randomised were not included in the analy-
sis (Faglia 1996a; Kessler 2003). One trial (Khandelwal 2013) re-
ported numbers of lost participants during follow-up, however, it
is unclear whether the analysis was performed on an intention-to-
treat basis. We judged these trials as being at high risk of bias. An-
other trial presenting results for an analysis of completers, reported
an imbalance of patient numbers withdrawing and the reasons for
withdrawal between treatment arms, this trial was judged to be at
high risk of bias (Wang 2011).
Selective reporting
We classified one trial for which a protocol was available as being
at low risk of bias (Londahl 2010). For another trial, all outcomes
detailed on a trials register were presented in the published report
(Wang 2011).We also classified this trial as low risk of bias. For the
remainder of the included published trials, no full protocol was
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available for inspection. As such, we classified all other included
trials as unclear risk of bias for this domain.
Effects of interventions
See: Summary of findings for the main comparisonHyperbaric
Oxygen Therapy for chronic wounds
Diabetic foot ulcers (10 trials)
Primary outcomes
We did not pre specify in the protocol for this review that we
anticipated multiple time points and we have presented data as
reported in the included trials.
Proportion of ulcers healed at end of treatment period (six
weeks)
Five trials reported this outcome (Abidia 2003; Kessler 2003;
Londahl 2010; Ma 2013; Khandelwal 2013), involving 205 par-
ticipants (39% of the total people with diabetes in this review),
with 99 participants randomised to shamor control and 106 to hy-
perbaric oxygen therapy (HBOT). The trial by Khandelwal 2013
contributes 75.1%of the weight to this analysis.Ma 2013 reported
in both arms of the study no events. Therefore, this study was
excluded from this meta-analysis. There was a statistically signifi-
cant increase in the proportion of ulcers healed following HBOT
compared with control (P = 0.01) (risk ratio (RR) 2.35, 95% con-
fidence interval (CI) 1.19 to 4.62 ; I2 = 4%) (Analysis 1.1). The
pre-planned sensitivity analysis examining the effect of allocation
of drop-outs suggested a benefit with HBOT in the best-case sce-
nario but not the worst-case scenario (best-case RR 4.61, 95% CI
2.35 to 9.08; P <0.00001, worst-case RR 0.84, 95% CI 0.51 to
1.37, P = 0.48) (Analysis 1.2; Analysis 1.3).
In terms of risk of bias, only two of the trials contributing to these
analyses provided detail of the randomisation process (Kessler
2003; Ma 2013) and none reported allocation concealment. Only
two studies performed blinding of patients (Abidia 2003; Londahl
2010) and were considered as low risk; Kessler 2003; Khandelwal
2013; and Ma 2013 were assessed as high risk of performance bias
due to study design (no sham therapy). Threewere considered to be
at low risk of bias in terms of blinded outcome assessment (Abidia
2003; Kessler 2003; Londahl 2010) and two were considered to be
at unclear risk (Khandelwal 2013; Ma 2013). Only Londahl 2010
presented a valid intention-to treat by including all participants
randomised in the final analysis and was considered at low risk of
attrition bias. Abidia 2003 , Kessler 2003, and Khandelwal 2013
each excluded participants who withdrew from their analyses and
were at high risk of bias for this domain.
One trial with 41 participants (47 ulcers) assigned to extracor-
poreal shockwave therapy (ESWT) and 45 participants (47 ul-
cers) to HBOT (Wang 2011) reported this outcome. The unit of
analysis reported was ulcers and the investigators reported a per-
protocol analysis showing a statistically significant difference in
the proportion of ulcers healed following HBOT compared with
ESWT following treatment (P = 0.003). However, as the number
of participants healing was not reported the findings could not be
confirmed. This trial was considered to be at high risk of perfor-
mance bias and at high risk of attrition bias as participants who
withdrew were excluded from the analysis.
Proportion of ulcers healed at six months
Two trials (112 participants) involved 30% of the total diabetic
population in this review (Abidia 2003; Londahl 2010), with 54
participants randomised to sham or control and 58 to HBOT.
There was no significant increase in the proportion of ulcers healed
following HBOT (RR 1.70, 95% CI 0.90 to 3.20, P = 0.10, I2 =
0%) (Analysis 1.4). The sensitivity analysis examining the effect
of allocation of drop-outs suggested a benefit with HBOT only in
the best-case scenario (RR 2.71, 95%CI 1.53 to 4.83, P = 0.0007,
I2 = 0%; worst-case: RR 0.93, 95% CI 0.57 to 1.54, P = 0.79, I
2 = 24%) (Analysis 1.5; Analysis 1.6). Neither trial reported on
the randomisation or allocation process, but both reported that
all participants and outcome assessors were blind to treatment
allocation. However, only the trial by Londahl 2010 presented a
valid intention-to -treat.
Proportion of ulcers healed at one year
Three trials involved 212 participants (58% of the total diabetic
participants in this review) (Abidia 2003; Duzgun 2008; Londahl
2010), with 104 randomised to shamor control and108 toHBOT.
Two trials reported no ulcers healed in the control arm (Abidia
2003; Duzgun 2008). A high level of between-trial heterogeneity
was evident for this comparison (I2 = 85%). In the original review
the data was analysed as failure to heal rather than ulcers healed
and demonstrated a significant effect in favour of HBOT. For this
update, we presented the RR of healing in order to facilitate ease of
interpretation for the reader of the healing outcomes. The inter-
pretation of the RR was that a summary estimate in which HBOT
increased the occurrence of healing would have a RR > 1.00. The
pooled random-effects model showed no statistically significant
difference between the groups (RR 9.53, 95% CI 0.44 to 207.76;
P = 0.15) (Analysis 1.7). This change in the result is mainly due to
the fact that there are a small number of trials with small sample
sizes, two of which have no events in the control arm. We took
statistical advice which indicated that this made the random-ef-
fects model for RR of healing unstable in these circumstances and
repeated the analysis using a Peto odds ratio (OR) (OR, 7.58, 95%
CI 4.33 to 13.29; P <0.00001) (Analysis 1.8). However, we must
approach all these results with caution.
The sensitivity analysis examining the effect of allocation of drop-
outs shows no statistically significant difference between the two
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groups in either best-case or worst-case scenario (Analysis 1.9;
Analysis 1.10). The trial by Duzgun 2008 was judged to be at
overall unclear risk of bias.
Proportion of participants requiring major amputation
Five trials (309 participants) reported this outcome at final fol-
low-up (Doctor 1992 (at discharge); Faglia 1996a (seven weeks);
Abidia 2003; Londahl 2010 (one year) and Duzgun 2008 (up to
92 weeks)); 159 were randomised to HBOT, 150 to sham or con-
trol. There was no statistically significant reduction in amputation
rate with the application of HBOT (the RR of major amputation
with HBOT was 0.36, 95% CI 0.11 to 1.18, P = 0.08, I2 = 50%)
(Analysis 1.11). This result was sensitive to the assumptions made
about drop-outs (best-case RR of amputation 0.20, 95% CI 0.10
to 0.38, P < 0.00001, worst-case 0.62, 95% CI 0.13 to 2.98, P =
0.55) (Analysis 1.12; Analysis 1.13). Subgroup analysis by number
of treatments did not significantly affect this outcome, with a RR
for amputation after 30 or more treatments of 0.40 (95% CI 0.07
to 2.23, P = 0.29). For < 30 treatments the RR was 0.29, 95% CI
0.07 to 1.16, P = 0.08 (Analysis 1.11). A post hoc subgroup analysis
according to the use of sham therapy compared with no sham in-
dicated a significant effect of treatment effect only amongst trials
with no sham procedure as control (RR of amputation, HBOT
compared with sham 0.47, 95% CI 0.09 to 2.44, P = 0.37; RR
HBOT compared to control without sham 0.15, 95% CI 0.06
to 0.36, P < 0.0001) (Analysis 1.14). The trial by Doctor 1992
was judged to be at high risk of performance bias and all other
methodological quality aspects as unclear risk of bias. The trial by
Faglia 1996a was judged as unclear risk of selection bias, perfor-
mance bias, detection bias and reporting bias, and as at high risk of
performance bias and attrition bias as participants who withdrew
were excluded from the analysis. The study by Duzgun 2008 were
considered as high risk of performance bias as the control arm did
not receive a sham treatment.
Secondary outcomes
Proportion of participants requiring minor amputation
Four trials (242 participants) reported this outcome at final follow-
up (Doctor 1992; Abidia 2003; Duzgun 2008; Londahl 2010),
123 were randomised to HBOT compared with 119 to sham or
control. There was no statistically significant change in rates of
minor amputation with the application of HBOT (the RR of
minor amputationwithHBOTwas 0.76, 95%CI0.19 to 3.10, P =
0.71, I2 = 70%) (Analysis 1.15). This result was not sensitive to the
allocation of drop-outs (best-case RR of amputation 0.55, 95%CI
0.17 to 1.75, P = 0.31, I2 = 63%,worst-case RR0.91, 95%CI 0.21
to 4.02, P = 0.90, I2 = 75%) (Analysis 1.16; Analysis 1.17). The
analyses for this outcome may be subject to considerable between-
trial heterogeneity as indicated by the high I2 values (random
effects), and these pooled results should be treated with caution.
Transcutaneous oxygen tension change in affected foot after
treatment
Only one trial contributed results to this outcome (Faglia 1996a)
involving 70 participants, 36 randomised to HBOT and 34 to a
control regimen. Two participants were not included in the analy-
sis (one control, one HBOT). There was a significantly greater in-
crease in transcutaneous oxygen tension followingHBOT(HBOT
14mmHg, sham 5mmHg,mean difference (MD) 9mmHg, 95%
CI 4.7 to 13.3, P = 0.0001) (Analysis 1.18). However this is a sur-
rogate outcome measure and was not pre specified in the protocol
for this review.
Absolute transcutaneous oxygen tensions in affected foot
after treatment
Three trials (117 participants) (Faglia 1996a; Lin 2001; Abidia
2003) randomised 62 people to HBOT, 55 to control. Faglia
1996a contributed 59% of the participants to this analysis, and
four participants were not included in the final analysis (two con-
trol, two HBOT). Transcutaneous oxygen tensions in the affected
foot were significantly higher in those participants who had re-
ceived HBOT (HBOT 11.8 mmHg higher, 95% CI 5.7 to 17.8,
P = 0.0002, I2 = 25.4%) (Analysis 1.19). However this is a surro-
gate outcome measure and was not pre specified in the protocol
for this review.
Wound size reduction
Two trials (63 participants) reported this outcome (Kessler 2003;
Ma 2013). The trial fromKessler 2003 (27 participants) suggested
ulcer healing was more rapid initially following treatment (after
two weeks ulcers in the HBOT group had reduced by 41.8%,
compared with 21.7% in the control group). A significant differ-
ence was reported (P = 0.04). However, four weeks following the
completion of therapy there was no difference in the mean ul-
cer area reduction between the two groups (HBOT 48.1% versus
41.7%, MD 6.4%, 95% CI -15.3 to 28.1) (Analysis 1.20). This
is a small trial which did not report a sample size calculation and
may have been underpowered to detect any statistically significant
effect. Whilst no between-group differences in mean ulcer size or
duration at baseline were evident from the trial report, no covari-
ate adjusted analyses were reported as being undertaken. The trial
recruited people with “ early diabetic feet”, Wagner grades 0, 1 or
2. The addition of the trial fromMa 2013 to the analysis suggested
a statistically significant increased mean ulcer area reduction (P
= 0.03) following HBOT compared with control at the end of
the treatment (MD 18.10, 95% CI 1.40 to 34.79 ; I2 = 54%)
(Analysis 1.20).This trial contributes to 65.3% of the weight to
this analysis.
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Time to complete healing
No data were available for this outcome.
Quality of life
Only one trial reported a quality of life assessment in a subsequent
publication to the original article (Londahl 2010). In this trial
this outcome was assessed using the 36-Item Short-Form Health
Survey (McHorney 1993) for 23 of 49 participants assigned to
HBOT and 10 of 45 participants assigned to control at the one-
year follow-up. A significant improvement in the physical func-
tion role limitations due to emotional health and mental health
summary score was reported in the HBOT group (P < 0.05). No
statistically significant improvements were reported for any do-
main amongst the control group. There was no difference between
the two groups on the overall physical summary score (MD -0.20,
95% CI -8.58 to 8.18, P = 0.96), or the overall mental summary
score (MD6.60, 95% CI -3.93 to 17.13, P = 0.22) (Analysis 1.21;
Analysis 1.22).
Recurrence rate
No data were available for this outcome.
Venous ulcers (1 trial)
Primary outcomes
Proportion of ulcers healed at 18 weeks
One trial (16 participants) (Hammarlund 1994) randomised nine
people to HBOT and eight to sham. There was no statistically
significant increase in the proportionof ulcers healed in theHBOT
group compared with sham treatment (RR 5.00, 95% CI 0.28 to
90.18, P = 0.28) (Analysis 2.1). The sensitivity analysis examining
the effect of allocation of drop-outs using a best-case (all drop-
outs in active group deemed successes, all drop-outs in sham group
deemed failures) and worse-case (all drop-outs in the active group
deemed failures, all in the sham group deemed successes) did not
alter the result (best-case RR 9.00, 95% CI 0.56 to 143.89, P =
0.12,worst-caseRR0.67, 95%CI0.15 to 2.98, P =0.60) (Analysis
2.2; Analysis 2.3).
In terms of risk of bias, the study did not report methods for
the randomization process, for concealment of allocation or for
blinding of outcome assessors and was considered to be at unclear
risk of bias for these domains. However participants were blinded
and there were no withdrawals from the study.
Secondary outcomes
Reduction in wound area immediately after treatment (six
weeks)
Hammarlund 1994 found a significantly greater reduction in
wound area following HBOT. No between-group differences in
mean or median ulcer size were evident at baseline. Ulcer dura-
tion at baseline was not reported, although inclusion criteria was
for ulcers >1 year. No covariate adjusted analyses were reported.
This small trial did not report a sample size calculation and may
have been underpowered to detect any statistically significant ef-
fect. There was a reduction in wound area in the HBOT group
of 35.7% compared with 2.7% in the sham group (MD 33.00%,
95% CI 18.97 to 47.03, P < 0.00001) (Analysis 2.4).
Reduction in wound area at 18 weeks
Hammarlund 1994 reported that five participants were not in-
cluded in this analysis (three sham, twoHBOT). There was no sig-
nificant difference in wound area reduction (HBOT 55.8%, sham
29.6%; MD 29.6%, 95% CI -23.0 to 82.2, P = 0.27) (Analysis
2.5).
Quality of life, pain reduction and recurrence rates for
venous ulcers
No data were available for these outcomes.
Mixed ulcers (1 trial)
Primary outcomes
Healed at end of treatment (30 days)
Kaur 2012 enrolled patients with non-healing diabetic ulcers as
well as venous ulcers (“mixed ulcers types”) and reported this out-
come. The trial involved 30 participants, treated for 30 days, with
15 participants randomised to control and 15 to HBOT.
There was no statistically significant increase in the proportion of
ulcers healed following HBOT compared with control (P = 0.19)
(RR 7.0, 95% CI 0.39 to 124.83) (Analysis 3.1).
In terms of risk of bias, the study provided details of the random-
ization process but did not report methods for concealment of
allocation. The study was considered to be at unclear risk of bias
in terms of blinding of outcome assessors and high risk of bias in
terms of blinding of patients and personnel. No withdrawals were
described.
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Major amputations
Kaur 2012 reported this outcome at the endof treatment (30days).
There was no statistically significant reduction in the amputation
rate with the application of HBOT (RR 0.2, 95%CI 0.03 to 1.51,
P = 0.12) (Analysis 3.2).
Secondary outcomes
Periwound transcutaneous oxygen tensions at the end of
treatment
Kaur 2012 reported after 30 days, periwound TcPO2 improved
by 11.8 mgHg in the HBOT group (P = 0.01) and decreased by
5.7 mgHg from baseline value in the control group (P = 0.2). The
baselineTcPO2valueswere not statistically different betweenboth
groups (P = 0.407). The periwound transcutaneous oxygen ten-
sions in the affected tissue were significantly higher in those par-
ticipants who had received HBOT (HBOT 11.8 mmHg higher,
95% CI 5.7 to 17.8, P = 0.0002, I2 = 25.4%) (Analysis 3.3).
Ulcer area reduction (%)
Kaur 2012 found a significantly greater reduction in wound area
following HBOT. No between-group differences in the wound
tissue score were evident at baseline. Ulcer duration at baseline
was more than 4 weeks with median wound duration of 2 month
(interquartile range (IQR) 1-60) in theHBOTgroup compared to
2.5month (IQR1-36) in the control group. There was a reduction
in wound area in the HBOT group of 59.27% compared with
-2.61% in the control group (MD 61.88%, 95% CI 41.91 to
81.85, P < 0.00001) (Analysis 3.4).
Arterial and pressure ulcers
No eligible trials were identified investigating the use of HBOT
for these ulcers.
Adverse effects of HBOT
Two trials (Doctor 1992; Abidia 2003) stated explicitly that there
were no complications or adverse events as a result of HBOT.
Kessler 2003 reported one person in the HBOT group who was
removed from the trial due to barotraumaof the ear and inLondahl
2010, two participants were removed from treatment because of
claustrophobia - one in each arm of this sham-controlled trial.
Kaur 2012 reported in the HBOT group three patients with ear
pain, two patients with claustrophobia, one patient with tinnitus,
and one patient with headache. The other trials did not report on
adverse events or complications of therapy in either arm.
Summary of Findings Table
We have included a Summary of Findings table in this review
(Summary of findings for the main comparison), which gives a
concise overview and synthesis of the volume and quality of the
evidence. The Summary of Findings table confirms our conclusion
that the evidence is of moderate quality and on balance there is
no strong evidence of a benefit of using HBOT for healing foot
ulcers in people with diabetes.
D I S C U S S I O N
This review has included data from twelve trials, ten of which
recruited people with diabetic foot ulcers. We believe these rep-
resent all randomised controlled trials (RCTs) in this area, both
published and unpublished at the time of searching the databases.
For the update, we presented a risk ratio (RR) of healing with hy-
perbaric oxygen therapy (HBOT), as opposed to a RR of failing
to heal without HBOT (i.e. control) as presented in the original
review. This was undertaken in order to facilitate ease of interpre-
tation of the healing outcomes for users of this review. We found
evidence from five trials that the addition of HBOT to a stan-
dard wound care regimen results in a significant improvement in
wound healing by six weeks (RR 2.35; P = 0.01), but this benefit
is not evident at longer-term follow-up (RR at one year or longer
9.53; P = 0.15). This was in contrast to this outcome presented as
the RR of failing to heal with control, as presented in the original
review, which was significant. However, the RR of healing at 12
months presented here should be interpreted with caution given
that the analyses included trials of varying sizes, some of which
had no healing events in the control arm. As such, the pooled es-
timation may be unreliable. Although we found some indication
amongst the included trials that HBOT may decrease the major
amputation rate in people with diabetic foot lesions, our pooled
estimate was not statistically significant (RR 0.36, 95% CI 0.11
to 1.18, P = 0.08).
We found no evidence that HBOT increases the healing of venous
ulcers, arterial or pressure ulcers.
Eleven trials with 491 participants in total were eligible for data
pooling according to the planned analyses, and ameta-analysis was
not possible for many of the outcomes of interest for this review.
Amongst the majority of the included trials, the reporting of a
number of aspects of trial conduct to inform the risk of bias assess-
ment was unclear. Only one of the trials reported sufficient detail
to indicate in most of the quality aspects low risk of bias (Londahl
2010; Figure 1). Blinding of participants was only reported in
three trials (Hammarlund 1994; Abidia 2003; Londahl 2010) and
blinding of outcome assessors was only reported in three trials
(Abidia 2003; Kessler 2003; Londahl 2010). Trials where blinding
was not undertaken may have introduced a performance and de-
tection bias to the results. It is not clear which of these factors is the
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more important in determining the different effect on the risk of
major amputation when comparing those who were blinded with
those who were not (Analysis 1.14). There is also a possibility that
some of the included trials may have been underpowered to detect
a statistically significant effect of HBOT on healing or amputa-
tion rates. Other limitations that should be considered include the
variability in the participant inclusion criteria across trials and the
nature and timing of outcome assessments. In particular, there is
a possibility of clinical heterogeneity due to differential wound
size or severity across trials at participant enrolment. The trial by
Londahl 2010, for example, excluded all participants at high risk
of major amputation. Excluding this trial from the analysis (data
not presented) resulted in a significant effect of HBOT on de-
creasing the risk of major amputation (P = 0.009).
The included trials were published over a 22-year period up to
2014. We had planned to perform subgroup analyses with respect
to wound grade at trial enrolment, oxygen dose (treatment profile
and number of treatments) and comparator therapy, however the
paucity of eligible trials and poor reporting suggested the majority
of these analyses would not be informative, and we only performed
some subgroup analyses in diabetic ulcer trials. Overall patient
inclusion criteria were not standard across trials and were poorly
reported in some trials. The oxygen dose at each treatment was
fairly consistent across trials, the lowest being 2.2 ATA for some
participants in Faglia 1996a, while the highest was 3.0 ATA in
Doctor 1992. The total number of treatments was similar in all
trials except Doctor 1992, where only four treatments were ad-
ministered over four weeks.While subgroup analysis by treatment
number suggests the benefit of HBOT on major amputation rate
was significant with either the short course or long course (> 30
treatment course: RR 0.40, P = 0.29; < 30 treatment course: RR
0.29, P = 0.08, ), this result should be interpreted with caution
given the contribution of the trial by Londahl 2010 previously
discussed. While all trials included in the meta-analysis compared
HBOT with some form of ’standard’ wound care, these compara-
tor therapies were generally poorly described and could not form
the basis for a meaningful subgroup analysis with the exception of
the analysis of the use of a HBOT sham or no sham as comparator.
Pooled data for clinical outcomes of interest could only be per-
formed for diabetic foot lesions with respect to the proportion
healed, and the risk of major and minor amputation. The analysis
of the rate of major amputation was heterogenous (I2 = 50%), sug-
gesting a between-study variance that could not be explained by
random variability. The risk of bias of the included trials was vari-
able. The limited reporting of trial methodology in some reports
(Doctor 1992; Duzgun 2008) resulted in an unclear risk of bias
associated with the effect estimates these trials contributed to the
pooled analyses. There were likely to be clinical differences in the
individuals recruited to the included trials. The trial by Londahl
2010 excluded participants where major amputation was likely,
while the other trials included a wider range of severity. Subgroup
analysis by the number of treatment sessions delivered did not
assist in the interpretation of this heterogeneity. Furthermore, it
is not clear if the surgical decision to amputate was made while
blinded to treatment allocation. This is an important potential
source of bias and thus a threat to validity.
In general, the findings of this review are comparable to those of
a previous review (Wang 2003). Wang considered all published
comparative trials and case series including at least five partici-
pants, and concluded that, while the included trials suggested that
HBOTmight be of benefit in nonhealing diabetic ulcers, the over-
all trial quality was poor and there was insufficient evidence to
recommend an appropriate time to initiate therapy. Further high-
quality RCTs were recommended to examine short and long-term
risks and benefits.
For venous ulceration we retrieved only one small trial (
Hammarlund 1994) which indicated a significant reduction in
wound area at six weeks following the administration of HBOT
(33% mean difference (MD) in area ulcerated, 95% CI 19 to 47).
This effect did not persist to 18 weeks and there was no significant
increase in the proportion of ulcers healed at any time. While this
trial suffered considerable data loss at 18 weeks, these results were
not sensitive to the allocation of drop-outs. For arterial and de-
cubitus ulceration we could locate no eligible trials and therefore
have no data on which to evaluate the efficacy of HBOT for these
ulcers.
In this update, we identified one trial (Kaur 2012) which enrolled
patients with different comorbidities and therefore different types
of ulcers. Due to the possibility that in future more studies of this
types will be found, we decided to add this as a new comparison
termed “mixed ulcers types” to the analysis. For this “mixed ulcers”
there was a significant benefit of HBOT in terms of reduction in
ulcer area at the end of treatment (30 days) but no statistically
significant difference in the healing rate of ulcers at the end of
treatment or the rate of major amputation.
All of these findings are subject to a potential publication bias.
While we have made every effort to locate further unpublished
data, it remains possible that this review is subject to a positive
publication bias, with generally favourable trials more likely to
achieve reporting.
With regard to long-term outcomes following HBOT, we have
located no relevant data. Only one trial reported a quality of life
assessment in a parallel publication (Londahl 2010), where no be-
tween-group differences in the physical or mental health summary
scores of the SF-36 were evident. However, data were reported
only for the completers of the quality of life assessment and as such
an attrition bias may be present in the quality of life results. One
trial evaluated the economic impact of the application of HBOT
(Abidia 2003) and this trial suggested a saving of GBP 2960 on
average per patient in the year following the HBOT. The savings
were related to a large reduction in the number of visits required
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for dressings in the first year (34 versus 137). However, reliability
of this analysis is not clear. The methodology was not reported and
we have no information regarding the influence of treatment allo-
cation on clinical decisions made during the period of economic
evaluation. Therefore, these findings should be handled with cau-
tion until more valid data are available.
None of the included trials reported major adverse outcomes in
either arm, and therefore we can report no data relating to risk
with which to balance the benefit estimated. HBOT is regarded
as a relatively benign intervention. There are few major adverse
effects (pulmonary barotrauma, drug reactions, injuries or death
related to chamber fire) and while these are all rare enough not
to expect to see them in the trials included in this review, they
should be included in consideration of the benefit of this therapy.
In practice it is likely that a beneficial effect strong enough to be
clearly identified in clinical trials would overwhelm the considera-
tion of such rare events. There are however, a number of more mi-
nor complications that may occur commonly and several authors
reported on these. Visual disturbance, usually reduction in visual
acuity secondary to conformational changes in the lens, is very
commonly reported - perhaps as many as 50% of those having a
course of 30 treatments (Khan 2003). While the great majority of
participants recover spontaneously over a period of days to weeks,
a small proportion of participants continue to require correction
to restore sight to pre-treatment levels. The second most common
adverse effect associated with HBOT is aural barotrauma. Baro-
trauma can affect any air-filled cavity in the body (including the
middle ear, lungs and respiratory sinuses) and occurs as a direct re-
sult of compression. Aural barotrauma is by far the most common
as the middle ear air space is small, largely surrounded by bone
and the sensitive tympanic membrane, and usually requires active
effort by the patient in order to inflate the middle ear through
the Eustachian tube on each side. Barotrauma is thus not a con-
sequence of HBOT directly, but rather of the physical conditions
required to administer it. Most episodes of barotrauma are mild,
easily treated or recover spontaneously and do not require the ther-
apy to be abandoned.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is some evidence that the addition of HBOT to a standard
wound care regimen in people with foot ulcers due to diabetes re-
sults in a significant improvement in wound healing by six weeks,
but this benefit is not evident at longer-term follow-up at one
year or longer. In terms of amputation, HBOT does not appear
to significantly improve the minor amputation rate in people with
foot ulcers due to diabetes, while a potentially important effect
on major amputation cannot be confirmed on this analysis. These
findings are limited by trials recruiting small numbers of partici-
pants with diverse wound characteristics and by trial reporting and
methodological discrepancies that present the potential to bias re-
sults. As such, these findings require a cautious interpretation. To
date no informative conclusions regarding the effects ofHBOT for
chronic wounds with other underlying pathologies can be made.
Implications for research
There is a strong case for further better-reported, large randomised
trials of high methodological rigour in order to define the true
extent of benefit from the administration of HBOT. Specifically,
more information is required on the subset of disease severity or
classification most likely to benefit from this therapy, the time
for which we can expect any benefits to persist, and the oxygen
dose most appropriate. An economic evaluation should also be
undertaken. Any future trials would need to consider in particular:
• appropriate sample sizes with power to detect expected
differences;
• careful definition and selection of target participants;
• appropriate oxygen dose per treatment session (pressure and
time);
• appropriate comparator therapy;
• use of an effective sham therapy;
• effective and explicit blinding of outcome assessors and
surgeons;
• appropriate outcome measures including all those listed in
this review;
• careful elucidation of any adverse effects; and
• the cost-utility of the therapy.
There is a strong case for investigation of the effects of HBOT on
chronic wounds due to venous disease, arterial disease and pressure
damage, in large, rigorous randomised clinical trials. Future trials
should consider the items andoutcomes as stated above for diabetic
foot ulcers.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abidia 2003
Methods Randomised controlled trial. Allocation concealed at enrolment. Participants, “carers”
(including the surgeons) and observers (“medical assessors”) blinded
Participants 18 people with diabetes with lower-extremity ulcers 1 to 10 cm in diameter that had not
shown signs of healing > 6 weeks since presenting
Group 1: 9 randomised
Group 2: 9 randomised
Interventions Group 1: hyperbaric air (control)
Group 2: 100% oxygen (treatment)
In a multi-place chamber via hood at a pressure of 2.4 atmospheres absolute (ATA) for 90
minutes daily, 5 days per week, totaling 30 sessions. All participants regularly attended
a specialised multi-disciplinary clinic. Wound care was standardised for all participants.
Antibiotic therapy was given if there were clinical signs of infection
Outcomes Proportion of ulcers healed at week 6; at 6 months; at 1 year
Reduction in ulcer size at 6 weeks; at 6 months
Major amputation; major amputation
Transcutaneous oxygen
Notes Quality of life undertaken using SF-36 and HADS. Cost-effectiveness analysis also un-
dertaken
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Mentions a “randomisation code” but no
statement of how randomisation sequence
was generated
Allocation concealment (selection bias) Unclear risk Quote: “The randomisation was per-
formed using sealed envelopes and the ran-
domisation code was only known to the
chamber operator.”
Comment: no statement that the envelopes
were sequentially numbered and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “All patients, their carers and medi-
cal assessors were blinded to the treatment.
”
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Abidia 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All patients, their carers and medi-
cal assessors were blinded to the treatment.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Two patients withdrew during
the course of the study (one in the con-
trol group required urgent vascular inter-
vention and one in the treatment group
dropped out for personal reasons)”
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
High risk Quote: “Data analysis was on an intention-
to-treat basis.”
“Two patients withdrew during the course
of the study (one in the control group
required urgent vascular intervention and
one in the
treatment group dropped out for personal
reasons)”
“At 6 weeks follow-up, complete healing
was achieved infive out of eight ulcers in the
treatment group compared with one out of
eight ulcers in the control group.”
Comment: although an intention-to treat-
design was stipulated, the two patients
withdrawing were not included in the final
analysis
Selective reporting (reporting bias) Unclear risk No protocol available. Most of the out-
comes described in methods section are re-
ported, however only the depression scale
for HADS is reported and only as P values
(significant)
Doctor 1992
Methods Randomised controlled trial. No blinding reported
Participants 30 people with diabetes referred with chronic foot lesion
Group 1: 15
Group 2: 15
Interventions Group 1: HBOT at 3.0 ATA on 4 occasions over 4 weeks
Group 2: standard care consisting of a specified surgical and dressing regimen
Outcomes Major amputations
Minor amputations
Hospital stay
Skin graft/stump healing/infection
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Doctor 1992 (Continued)
Positive wound cultures
Notes Unusual HBOT regimen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The patients were randomly allot-
ted to one of the two groups”
Comment: no description of sequence gen-
eration
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No statement on blinding of patients. Since
the control group received only conven-
tional treatment and no sham therapy, the
patients were unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No statement on withdrawals
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
Unclear risk There is no statement as to whether the
presented results are for all patients who
entered the trial or otherwise
Selective reporting (reporting bias) Unclear risk No protocol available, but all outcomes in
methods section are reported in results
Duzgun 2008
Methods Randomised controlled trial of standard wound therapy versus standard therapy plus
HBOT. No blinding attempted, but random number table used and primary outcome
unlikely to be subject to bias
Participants 100 adults with diabetes requiring admission to hospital with “infected foot ulceration”
for at least 4 weeks and who had received “appropriate local and systemic wound care”
Group 1: 50 randomised
Group 2: 50 randomised
Interventions Group 1: standard care
Group 2: HBOT
Standard care “entailed daily wound care, including dressing changes and local debride-
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Duzgun 2008 (Continued)
ment at bedside or in the operating room, as well as amputation when indicated. Infec-
tion controls were carried out by clinical follow-up, and by performing culture-antibi-
ograms of surgically obtained specimens to determine appropriate antibiotic therapy.”
In the HBOT group, standard therapy was supplemented by 100% oxygen at 2.0 ATA
for 90 minutes twice one day and once the next day, alternating for 20 to 30 days. Actual
course probably determined by clinical response
Outcomes Total closure of the wound without the need for surgical intervention (healed)
Graft or flap closure required to attain healing
Amputation distal to the metatarsophalangeal joints (distal amputation)
Amputation proximal to the metatarsophalangeal joints (proximal amputation)
No change
Operative surgical debridement (in the operating room) of the wound was all that was
required to achieve closure
Notes Long course of HBOT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were randomly assigned..
.using a random number table”
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No statement on blinding of patients. Since
the control group received only standard
treatment and no sham therapy, the pa-
tients were unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No statement on withdrawals
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
Unclear risk There is no statement as to whether the
presented results are an ITT analysis or that
all participants completed the trial
Selective reporting (reporting bias) Unclear risk No protocol available, but all outcomes in
methods section are reported in results
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Faglia 1996a
Methods Randomised controlled trial. No blinding reported
Participants 70 people with diabetes and a foot lesion Wagner grade 2 to 4
Group 1: 33 randomised
Group 2: 37 randomised
Interventions Group 1: standard care consisting of a specialised multidisciplinary wound management
programme
Group 2: HBOT at 2.2 to 2.5 ATA for 90 minutes on an average of 39 occasions over
about 6 weeks
Outcomes Major amputation
Transcutaneous oxygen
Minor amputations
Vascular procedures
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were allocated to treatment arms
by consulting a table of random numbers
at the hospital
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No statement on blinding of patients. Since
the control group received only conven-
tional treatment and no sham therapy, the
patients were unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk One HBOT patient refused treatment and
one HBOT patient died
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
High risk Quote: “Both these subjects were excluded
from the analysis of the results.”
Selective reporting (reporting bias) Unclear risk No protocol available, but all outcomes in
methods section are reported in results
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Hammarlund 1994
Methods Randomised, double-blind controlled trial
Participants 16 patients with leg ulcers of more than 1 year duration
Group 1: 8 randomised
Group 2: 8 randomised
Interventions Group 1: breathing sham treatment on the same schedule as HBOT
Group 2: HBOT at 2.5 ATA for 90 minutes on 30 occasions over 6 weeks
Outcomes Ulcer healing
Reduction in wound area
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised according to age,
but no statement of how randomisation se-
quence was generated
Quote: “The patients were put into two
categories according to age and then ran-
domly assigned to two groups.”
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The gas supply was blinded to all
persons involved”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All patients went through the 30
treatments”
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
Low risk Quote: “All patients went through the 30
treatments”
Selective reporting (reporting bias) Unclear risk No protocol available, but all outcomes in
methods section are reported in results
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Kaur 2012
Methods Randomized, controlled trial. No blinding reported, no sham therapy offered
Participants 30 adult patients with nonhealing ulcer, despite conventional therapy of more than 4
weeks duration
Group 1: 15 randomized
Group 2: 15 randomized
Interventions Group 1: Patients received only conventional treatment for management of wounds, i.
e., wound debridement, treating infection, daily dressing, which was managed by the
referring surgeon
Group 2: Patients received conventional treatment plus HBOT for 90 min at 2.5 ATA
daily, 6 days a week, a total of 30 sessions
Outcomes Healed at final follow-up (30 days)
Major amputation (30 days)
Wound exudate resolved
Appearance of granulation tissue
Surgical debridement
Wound size reduction
Transcutaneous oxygen
Adverse events (ear pain, claustrophobia, tinnitus, headache)
Notes Not all diabetic ulcers.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk computer-generated schedule
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No sham therapy offered.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients completed the study period.
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
Low risk No patient was excluded from the analysis.
Selective reporting (reporting bias) Unclear risk No protocol available, but all outcomes in
methods section are reported in results
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Kessler 2003
Methods Randomised controlled trial, no blinding
Participants 28 people with diabetes and Wagner grade I, II and III foot ulcers
Group 1: 13 randomised
Group 2: 15 randomised
All were admitted for care and had transcutaneous oxygen estimated at greater than 30
mmHg
Interventions Group 1: standard treatment including glycaemic control, offloading and wound care
Group 2: in addition, the HBOT group received twice-daily sessions breathing 100%
oxygen at 2.5 ATA for 90 minutes for 10 days (total 20 treatments)
Outcomes Changes in wound surface area
Transcutaneous oximetry
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised according to a
randomisation table
Quote: “..patients were randomised to stan-
dard treatment or standard treatment plus
HBO according to a randomisation table.”
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No statement on blinding of patients. Since
the control group received only conven-
tional treatment and no sham therapy, the
patients were unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Weekly tracings of the surface area
of the ulcer onto griddled transparent film
were performed by a physician blinded to
the patient’s group assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “HBO was well tolerated in all but
one patient, who demonstrated a barotrau-
matic otitis, for which he was discharged
from the study.”
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
High risk Quote: “HBO was well tolerated in all but
one patient, who demonstrated a barotrau-
matic otitis, for which he was discharged
from the study”
Comment: the participant was not included
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Kessler 2003 (Continued)
in final analysis.
Selective reporting (reporting bias) Unclear risk No protocol available, but all outcomes in
methods section are reported in results
Khandelwal 2013
Methods Randomised, controlled trial, no blinding
Participants 60 participants (35 to 65 years) with type 2 Diabetes mellitus which was adequately
controlled. Inclusion criteriawere: diabetic foot ulcer of at least 8weeks duration, patients
with only stage III and IV diabetic foot ulcer, absence of vascular insufficiency involving
large and medium sized arteries proximal to the ulcer demonstrated by Doppler study,
age ≥18 years with type 1 or 2 diabetes
Group 1 (“antiseptics”): 20 randomised
Group 2 (“HBOT”): 20 randomised
Group 3 (“platelet-derived growth factor therapy”): 20 randomised
Interventions Group 1: patients were surgically debrided and treated with EUSOL, hydrogen peroxide,
povidone iodine
Group 2: HBO therapy at 2.5 ATA for 60 min per sitting for a total of 30 sittings or till
the ulcer healed. These sittings were distributed over a period of 10 weeks. Patients were
given either daily or alternate day therapy depending on availability. Occasional wound
debridement. No anti-septics were used
Outcomes Healed at final follow-up (10 weeks)
Time to complete healing
Mean wound size
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information about the sequence gener-
ation process
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No sham therapy offered.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unlikely given the design.
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Khandelwal 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Incomplete outcome data. No reasons
mentioned for loss of patients during fol-
low-up
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
High risk Probably no intention-to-treat analysis.
Selective reporting (reporting bias) Unclear risk No protocol available, but all outcomes in
methods section are reported in results
Lin 2001
Methods Randomised controlled trial. Allocationmade after decision to enrol, and patient blinded
Participants 29 people with diabetes and foot lesions Wagner grade 0 to 2
Interventions Group 1: comparator not specified (sham/no treatment)
Group 2: HBOT at 2.5 ATA for 120 minutes daily to 30 treatments
Outcomes Transcutaneous oxygen
Notes Abstract only. Ulcers were generally less severe than comparable studies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “..patients were randomly assigned.
.”
Comment: patients were randomly as-
signed, but no details of sequence genera-
tion
Allocation concealment (selection bias) Low risk Author described information on alloca-
tion concealment on request
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No statement on blinding of patients. The
comparator was not specified
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No statement on withdrawals. Numbers at
analysis not stated.
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Lin 2001 (Continued)
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
Unclear risk Limited information in abstract to make a
judgement
Selective reporting (reporting bias) Unclear risk Limited information in abstract and sup-
plied to make a judgement
Londahl 2010
Methods Double-blind, randomised controlled trial with sham HBOT therapy
Participants 94 adults with diabetes and a foot ulcer (below the ankle) for at least 3 months. Wound
clinic treatment for at least 2 months and revascularisation not possible or not indicated
on vascular assessment
Group 1: 45 randomised
Group 2: 49 randomised
Interventions Group 1: sham
Group 2: HBOT
The study treatment was given as an adjunct to regular treatment at themultidisciplinary
diabetic foot clinic. HBOT was delivered at 2.5 ATA for 85 minutes daily fromMonday
to Friday to a total of 40 treatments over 8 to 10 weeks
The sham treatment was the same except the patients breathed air
Outcomes Complete healing of the index ulcer
Case-fatality rate 1 year
Major and minor amputation rate
Adverse reactions
Notes An independent steering committee was responsible for the organisation, data-handling
and general conduct of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was done in
blocks of 10”
Comment: but no statement of how ran-
domisation sequence was generated
Allocation concealment (selection bias) Unclear risk Quote: “using sealed envelopes”
Comment: no statement that the envelopes
were sequentially numbered and opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients from both groups could
be treated in the same session as study
gases were administered bymasks and air or
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Londahl 2010 (Continued)
100%oxygen entered the chamber through
separate double-blinded pipes”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A blinded clinical event committee
evaluated and classified all reported events
as well as clinical outcome.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers and reasons for withdrawal given
in study flow chart:
HBOT: claustrophobia, 1; hospitalisation,
3; amputation, 1; died, 1; no time, 1; with-
drew consent, 1
Placebo: claustrophobia, 1; hospitalisation,
2; amputation, 1; died, 1; no time, 2; with-
drew consent, 1
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
Low risk Quote: “Statistical evaluation was initially
performed as an intention-to-treat analysis.
”
Comment: Per-protocol and ITT analysis
presented. ITT analysis included all partic-
ipants randomised
Selective reporting (reporting bias) Low risk Protocol available and pre-specified out-
comes are all reported
Ma 2013
Methods Randomised, controlled trial, no blinding.
Participants 36 patients with diagnosed diabetes, at least one full-thickness wound below the ankle
(Wagner grades III or less) for > 3 month, standard care for > 2 month, TcPO2 > 30
mmHg
Group 1: 18 randomised
Group 2: 18 randomised
Interventions Group 1: Standard care consisting of offloading, footwear, oral antibiotics, monitoring
glucose levels, silver-impregnated dressings, daily debridement and cleaning
Group 2: Standard care in addition to HBOT twice daily at 2.5 ATA for 90 minutes, 5
days a week for 2 weeks
Outcomes Healed at final follow-up (2 weeks)
Wound size reduction
Notes
Risk of bias
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Ma 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation table
Allocation concealment (selection bias) Unclear risk Method of concealment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No sham therapy offered
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding of outcome as-
sessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study did not address this issue
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
Unclear risk The study did not address this issue
Selective reporting (reporting bias) Unclear risk No protocol available, but all outcomes in
methods section are reported in results
Wang 2011
Methods Open-label, randomised controlled trial
Participants 86 people with diabetes with 93 chronic non-healing ulcers in the foot area
Group 1: 41 randomised (46 ulcers)
Group 2: 45 randomised (47 ulcers)
Interventions Group 1: extracorporeal shockwave therapy (ESWT)
Group 2: HBOT
EWST treatment dose was ulcer size-dependent. Treatments were conducted 2 times per
week for 3 weeks for a total of 6 treatments. After ESWT, patients resumed their initial
wound care protocol. Administration of additional antibiotic was discretional
HBOTwas at a pressure of 2.5 ATA for 90minutes per treatment daily for a total 20 days
of treatments. Patients received the same standard wound care protocol after treatment
as ESWT
Outcomes Ulcers healed
Ulcers with ≥50% improvement
Unchanged ulcers
Worsened ulcers
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Wang 2011 (Continued)
Notes 27 patients (ESWT: 12 with 14 ulcers; HBOT: 15 with 17 ulcers) also received a second
course of treatment due to improved but incomplete healing of the ulcers 4 to 6 weeks
from the first treatment
The denominator used in the analysis was the number of ulcers not patients. Results
reported for completers. Clinical trial number NCT01219127
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised, but no statement
of how randomisation sequence was gener-
ated
Allocation concealment (selection bias) Unclear risk No statement on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “patients and healthcare providers
were not blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No statement on blinding of outcome asses-
sors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “During the course of treatment, 9
patients were excluded including 2 in the
ESWT group (2 poor compliance) and seven
in the HBO group (7 incomplete follow-up
data).”
Incomplete outcome data addressed (use of
intention-to-treat (ITT) analysis)
High risk Patients withdrawing were not balanced in
numbers across intervention groups, and rea-
sons were not similar across groups. Analysis
not undertaken using ITT
Selective reporting (reporting bias) Low risk All outcomes specified in trials register re-
ported in article
ATA: atmospheres absolute
HADS: Hospital Anxiety and Depression Scale
HBOT: hyperbaric oxygen therapy
ITT: intention-to-treat
SF-36: Short Form (36) Health Survey
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baroni 1987 Not randomised.
Chin 2001 No appropriate outcome data.
Cruz 2003 Not appropriate wound type.
Deng 2006 All patients received HBOT.
Efrati 2009 All patients received HBOT.
Faglia 1996b No appropriate outcome data.
Heng 1984 Topical oxygen, not HBOT.
Heng 2000 Topical oxygen, not HBOT.
Holbach 1978 Not randomised or actually dealing with chronic wounds.
Kalani 2000 Not all patients randomised. Authors could not identify randomised subset of the data
Kalani 2002 Not all patients randomised. Authors could not identify randomised subset of the data
Kaya 2009 No RCT
Londahl 2011 Follow up study to the included trial from Londahl 2010. No relevant outcome.
Mathieu 2011 Study protocol not undertaken.
Oriani 1990 Not randomised.
Perrins 1967 Acute burn wound.
Whelan 2001 Animal study.
Zamboni 1997 Not randomised.
HBOT: hyperbaric oxygen therapy
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Characteristics of ongoing studies [ordered by study ID]
O’Reilly 2011
Trial name or title Hyperbaric Oxygen Therapy (HBOT) for Chronic Diabetic Lower Limb Ulcers
Methods Randomised controlled trial
Participants People with diabetes and a non-healing lower limb ulcer
Interventions Patients allocated to active HBOT receive 90 minutes of oxygen at 2.4 ATA with the patients breathing 100%
oxygen when inside the chamber. Those patients randomised to placebo will be compressed on air to 0.3
ATA (10 feet) and kept at that level. The patient will remain in the chamber for the remainder of the placebo
treatment breathing normally. At the end of the treatment, after a short period of enhanced ventilation (to
simulate surfacing) the chamber will be opened. Patients enter the chambers 5 days per week for approximately
6 weeks for a total of 30 treatments. At the end of the 6-week treatment phase, patients enter a 6-week follow-
up phase
Outcomes The primary outcome in this study is freedom from having, or meeting the criteria for, a major amputation
(below knee amputation or metatarsal level) up to 12 weeks after initiation of treatment
Wound healing
Effectiveness
Safety
Healthcare resource utilisation
Quality of life
Cost effectiveness of HBOT
Starting date April 2008. Estimated completion Jan 2012.
Contact information Wilhelmine Jones, Reg. Nurse. 1-416-223-6600. willie.jones@uhn.on.ca
Notes ClinicalTrials.gov Identifier: NCT00621608
Stoekenbroek 2015
Trial name or title Dutch DAMOCLES multicenter randomized clinical trial
Methods Multicenter randomized clinical trial, including 30 hospitals and all 10 HBOT centers in the Netherlands. It
is planed to enrol 275 patients
Participants Patients with Types 1 or 2 diabetes, a Wagner 2, 3 or 4 ulcer of the leg present for at least 4 weeks, and
concomitant leg ischemia, defined as an ankle systolic blood pressure of <70 mmHg, a toe systolic blood
pressure of <50 mmHg or a forefoot transcutaneous oxygen tension (TcpO2) of <40 mmHg. Eligible patients
may be candidates for revascularization
Interventions Patients will be randomly assigned to standard care with or without 40 HBOT-sessions. This regimen consists
of forty 90-min treatment sessions at 2.5 ATA. We chose this number of sessions to make sure the HBOT
exerts its effect, if any. Patients will breathe 100% oxygen during the session, except for three blocks of 5 min
during which ambient air will be administered to prevent oxygen intoxication. Patients will be treated five
times per week, once daily, until the ulcer has fully re-epithelialized or until a
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Stoekenbroek 2015 (Continued)
maximum of 40 sessions has been reached.
Outcomes Primary outcome measures are freedom from major amputation after 12 months and achievement of, and
time to, complete wound healing. Secondary endpoints include freedom from minor amputations, ulcer
recurrence, TcpO2, quality of life, and safety. In addition, we will assess the cost-effectiveness
of HBOT for this indication.
Starting date July 2013
Contact information Dirk T. Ubbink, Department of Surgery, Room G4-184, Academic Medical Center, P.O. Box 22660, 1100
DD Amsterdam, the Netherlands
Notes http://www.trialregister.nl; NTR 3944
ATA: atmospheres absolute
HBOT: hyperbaric oxygen therapy
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D A T A A N D A N A L Y S E S
Comparison 1. Diabetic ulcers
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Healed at end of treatment (6
weeks)
5 205 Risk Ratio (M-H, Fixed, 95% CI) 2.35 [1.19, 4.62]
2 Healed at end of treatment.
Best-case.
5 216 Risk Ratio (M-H, Fixed, 95% CI) 4.61 [2.35, 9.08]
3 Healed at end of treatment.
Worst-case.
5 216 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.51, 1.37]
4 Healed at 6 months 2 112 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [0.90, 3.20]
5 Healed at 6 months. Best-case. 2 112 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [1.53, 4.83]
6 Healed at 6 months. Worst-case. 2 112 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.57, 1.54]
7 Healed at 1 year 3 212 Risk Ratio (M-H, Random, 95% CI) 9.53 [0.44, 207.76]
8 Healed at 1 year. Peto analysis
method.
3 212 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.58 [4.33, 13.29]
9 Healed at 1 year. Best-case. 3 212 Risk Ratio (M-H, Random, 95% CI) 10.17 [0.47, 220.48]
10 Healed at 1 year. Worst-case. 3 212 Risk Ratio (M-H, Random, 95% CI) 6.55 [0.42, 101.71]
11 Major amputations 5 312 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.11, 1.18]
11.1 Subgroup (30+
treatments)
4 282 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.07, 2.23]
11.2 Subgroup (< 30
treatments)
1 30 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.07, 1.16]
12 Major amputations. Best-case. 5 312 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.10, 0.38]
13Major amputations. Worst-case. 5 312 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.13, 2.98]
14 Major amputation subgroup by
use of sham
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Sham HBOT 2 112 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.09, 2.44]
14.2 No sham 3 200 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.06, 0.36]
15 Minor amputations 4 242 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.19, 3.10]
16 Minor amputations. Best-case. 4 242 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.17, 1.75]
17 Minor amputations.
Worst-case.
4 242 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.21, 4.02]
18 Transcutaneous oxygen
tensions change after treatment
1 68 Mean Difference (IV, Fixed, 95% CI) 9.0 [4.68, 13.32]
19 Absolute difference in
transcutaneous oxygen at end
of treatment
3 113 Mean Difference (IV, Fixed, 95% CI) 11.76 [5.68, 17.84]
20 Ulcer area reduction (%) 2 63 Mean Difference (IV, Random, 95% CI) 18.10 [1.40, 34.79]
21 Quality of life - SF-36 physical
summary score
1 33 Mean Difference (IV, Fixed, 95% CI) -0.20 [-8.58, 8.18]
22 Quality of life - SF-36 mental
summary score
1 33 Mean Difference (IV, Fixed, 95% CI) 6.60 [-3.93, 17.13]
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Comparison 2. Venous ulcers
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Healed at 18 weeks 1 16 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.28, 90.18]
2 Healed at 18 weeks. Best-case. 1 16 Risk Ratio (M-H, Fixed, 95% CI) 9.0 [0.56, 143.89]
3 Healed at 18 weeks. Worst-case. 1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.15, 2.98]
4 Wound size reduction at end
treatment (6 weeks)
1 16 Mean Difference (IV, Fixed, 95% CI) 33.0 [18.97, 47.03]
5 Wound size reduction at 18
weeks
1 11 Mean Difference (IV, Fixed, 95% CI) 29.60 [-22.99, 82.
19]
Comparison 3. Mixed ulcers types
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Healed at end of treatment (30
days)
1 30 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.39, 124.83]
2 Major amputations 1 30 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.03, 1.51]
3 Periwound transcutaneous
oxygen tensions at the end of
treatment
1 30 Mean Difference (IV, Fixed, 95% CI) 12.90 [4.00, 21.80]
4 Ulcer area reduction (%) 1 30 Mean Difference (IV, Fixed, 95% CI) 61.88 [41.91, 81.85]
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Analysis 1.1. Comparison 1 Diabetic ulcers, Outcome 1 Healed at end of treatment (6 weeks).
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 1 Healed at end of treatment (6 weeks)
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abidia 2003 5/9 1/9 12.1 % 5.00 [ 0.72, 34.73 ]
Kessler 2003 2/15 0/13 6.5 % 4.38 [ 0.23, 83.62 ]
Khandelwal 2013 9/15 6/14 75.1 % 1.40 [ 0.67, 2.91 ]
Londahl 2010 3/49 0/45 6.3 % 6.44 [ 0.34, 121.33 ]
Ma 2013 0/18 0/18 Not estimable
Total (95% CI) 106 99 100.0 % 2.35 [ 1.19, 4.62 ]
Total events: 19 (HBOT), 7 (Control)
Heterogeneity: Chi2 = 3.12, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours control Favours HBOT
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Analysis 1.2. Comparison 1 Diabetic ulcers, Outcome 2 Healed at end of treatment. Best-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 2 Healed at end of treatment. Best-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abidia 2003 6/9 1/9 12.4 % 6.00 [ 0.89, 40.31 ]
Kessler 2003 3/15 0/13 6.6 % 6.13 [ 0.35, 108.58 ]
Khandelwal 2013 14/20 6/20 74.5 % 2.33 [ 1.13, 4.83 ]
Londahl 2010 14/49 0/45 6.5 % 26.68 [ 1.64, 434.64 ]
Ma 2013 0/18 0/18 Not estimable
Total (95% CI) 111 105 100.0 % 4.61 [ 2.35, 9.08 ]
Total events: 37 (HBOT), 7 (Control)
Heterogeneity: Chi2 = 5.00, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 4.43 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours control Favours HBOT
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Analysis 1.3. Comparison 1 Diabetic ulcers, Outcome 3 Healed at end of treatment. Worst-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 3 Healed at end of treatment. Worst-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abidia 2003 5/9 2/9 8.9 % 2.50 [ 0.65, 9.69 ]
Kessler 2003 2/15 1/13 4.8 % 1.73 [ 0.18, 16.99 ]
Khandelwal 2013 9/20 12/20 53.6 % 0.75 [ 0.41, 1.37 ]
Londahl 2010 3/49 7/45 32.6 % 0.39 [ 0.11, 1.43 ]
Ma 2013 0/18 0/18 Not estimable
Total (95% CI) 111 105 100.0 % 0.84 [ 0.51, 1.37 ]
Total events: 19 (HBOT), 22 (Control)
Heterogeneity: Chi2 = 4.34, df = 3 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours control Favours HBOT
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Analysis 1.4. Comparison 1 Diabetic ulcers, Outcome 4 Healed at 6 months.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 4 Healed at 6 months
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abidia 2003 5/9 2/9 17.6 % 2.50 [ 0.65, 9.69 ]
Londahl 2010 15/49 9/45 82.4 % 1.53 [ 0.74, 3.15 ]
Total (95% CI) 58 54 100.0 % 1.70 [ 0.90, 3.20 ]
Total events: 20 (HBOT), 11 (Control)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours control Favours HBOT
Analysis 1.5. Comparison 1 Diabetic ulcers, Outcome 5 Healed at 6 months. Best-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 5 Healed at 6 months. Best-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abidia 2003 6/9 2/9 17.6 % 3.00 [ 0.81, 11.08 ]
Londahl 2010 26/49 9/45 82.4 % 2.65 [ 1.40, 5.04 ]
Total (95% CI) 58 54 100.0 % 2.71 [ 1.53, 4.83 ]
Total events: 32 (HBOT), 11 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 3.40 (P = 0.00067)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours HBOT
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Analysis 1.6. Comparison 1 Diabetic ulcers, Outcome 6 Healed at 6 months. Worst-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 6 Healed at 6 months. Worst-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abidia 2003 5/9 3/9 14.5 % 1.67 [ 0.56, 4.97 ]
Londahl 2010 15/49 17/45 85.5 % 0.81 [ 0.46, 1.42 ]
Total (95% CI) 58 54 100.0 % 0.93 [ 0.57, 1.54 ]
Total events: 20 (HBOT), 20 (Control)
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Diabetic ulcers, Outcome 7 Healed at 1 year.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 7 Healed at 1 year
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abidia 2003 5/9 0/9 30.3 % 11.00 [ 0.70, 173.66 ]
Duzgun 2008 33/50 0/50 30.2 % 67.00 [ 4.22, 1064.23 ]
Londahl 2010 25/49 12/45 39.5 % 1.91 [ 1.10, 3.34 ]
Total (95% CI) 108 104 100.0 % 9.53 [ 0.44, 207.76 ]
Total events: 63 (HBOT), 12 (Control)
Heterogeneity: Tau2 = 6.19; Chi2 = 13.75, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Diabetic ulcers, Outcome 8 Healed at 1 year. Peto analysis method..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 8 Healed at 1 year. Peto analysis method.
Study or subgroup HBOT Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Abidia 2003 5/9 0/9 7.8 % 13.67 [ 1.84, 101.50 ]
Duzgun 2008 33/50 0/50 45.8 % 19.21 [ 8.38, 44.02 ]
Londahl 2010 25/49 12/45 46.4 % 2.74 [ 1.20, 6.26 ]
Total (95% CI) 108 104 100.0 % 7.58 [ 4.33, 13.29 ]
Total events: 63 (HBOT), 12 (Control)
Heterogeneity: Chi2 = 11.00, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 7.08 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Diabetic ulcers, Outcome 9 Healed at 1 year. Best-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 9 Healed at 1 year. Best-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abidia 2003 6/9 0/9 30.3 % 13.00 [ 0.84, 201.26 ]
Duzgun 2008 33/50 0/50 30.2 % 67.00 [ 4.22, 1064.23 ]
Londahl 2010 26/49 12/45 39.5 % 1.99 [ 1.15, 3.45 ]
Total (95% CI) 108 104 100.0 % 10.17 [ 0.47, 220.48 ]
Total events: 65 (HBOT), 12 (Control)
Heterogeneity: Tau2 = 6.16; Chi2 = 13.81, df = 2 (P = 0.001); I2 =86%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Diabetic ulcers, Outcome 10 Healed at 1 year. Worst-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 10 Healed at 1 year. Worst-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abidia 2003 5/9 1/9 32.9 % 5.00 [ 0.72, 34.73 ]
Duzgun 2008 33/50 0/50 28.1 % 67.00 [ 4.22, 1064.23 ]
Londahl 2010 25/49 15/45 38.9 % 1.53 [ 0.93, 2.51 ]
Total (95% CI) 108 104 100.0 % 6.55 [ 0.42, 101.71 ]
Total events: 63 (HBOT), 16 (Control)
Heterogeneity: Tau2 = 4.97; Chi2 = 16.10, df = 2 (P = 0.00032); I2 =88%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Diabetic ulcers, Outcome 11 Major amputations.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 11 Major amputations
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Subgroup (30+ treatments)
Abidia 2003 1/9 1/9 13.9 % 1.00 [ 0.07, 13.64 ]
Duzgun 2008 0/50 17/50 12.7 % 0.03 [ 0.00, 0.46 ]
Faglia 1996a 3/36 11/34 29.8 % 0.26 [ 0.08, 0.84 ]
Londahl 2010 3/49 1/45 17.0 % 2.76 [ 0.30, 25.54 ]
Subtotal (95% CI) 144 138 73.3 % 0.40 [ 0.07, 2.23 ]
Total events: 7 (HBOT), 30 (Control)
Heterogeneity: Tau2 = 1.90; Chi2 = 8.08, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.05 (P = 0.29)
2 Subgroup (< 30 treatments)
Doctor 1992 2/15 7/15 26.7 % 0.29 [ 0.07, 1.16 ]
Subtotal (95% CI) 15 15 26.7 % 0.29 [ 0.07, 1.16 ]
Total events: 2 (HBOT), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
Total (95% CI) 159 153 100.0 % 0.36 [ 0.11, 1.18 ]
Total events: 9 (HBOT), 37 (Control)
Heterogeneity: Tau2 = 0.86; Chi2 = 7.99, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.77), I2 =0.0%
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Analysis 1.12. Comparison 1 Diabetic ulcers, Outcome 12 Major amputations. Best-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 12 Major amputations. Best-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Abidia 2003 1/9 2/9 4.2 % 0.50 [ 0.05, 4.58 ]
Doctor 1992 2/15 7/15 14.8 % 0.29 [ 0.07, 1.16 ]
Duzgun 2008 0/50 17/50 37.1 % 0.03 [ 0.00, 0.46 ]
Faglia 1996a 3/36 12/34 26.2 % 0.24 [ 0.07, 0.76 ]
Londahl 2010 3/49 8/45 17.7 % 0.34 [ 0.10, 1.22 ]
Total (95% CI) 159 153 100.0 % 0.20 [ 0.10, 0.38 ]
Total events: 9 (HBOT), 46 (Control)
Heterogeneity: Chi2 = 3.64, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 4.80 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Diabetic ulcers, Outcome 13 Major amputations. Worst-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 13 Major amputations. Worst-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abidia 2003 2/9 1/9 18.0 % 2.00 [ 0.22, 18.33 ]
Doctor 1992 2/15 7/15 22.9 % 0.29 [ 0.07, 1.16 ]
Duzgun 2008 0/50 17/50 14.9 % 0.03 [ 0.00, 0.46 ]
Faglia 1996a 4/36 11/34 24.9 % 0.34 [ 0.12, 0.98 ]
Londahl 2010 13/49 1/45 19.3 % 11.94 [ 1.63, 87.63 ]
Total (95% CI) 159 153 100.0 % 0.62 [ 0.13, 2.98 ]
Total events: 21 (HBOT), 37 (Control)
Heterogeneity: Tau2 = 2.30; Chi2 = 16.42, df = 4 (P = 0.003); I2 =76%
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Diabetic ulcers, Outcome 14 Major amputation subgroup by use of sham.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 14 Major amputation subgroup by use of sham
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Sham HBOT
Abidia 2003 1/9 1/9 24.2 % 1.00 [ 0.07, 13.64 ]
Londahl 2010 1/49 3/45 75.8 % 0.31 [ 0.03, 2.84 ]
Subtotal (95% CI) 58 54 100.0 % 0.47 [ 0.09, 2.44 ]
Total events: 2 (HBOT), 4 (Control)
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 No sham
Doctor 1992 2/15 7/15 19.5 % 0.29 [ 0.07, 1.16 ]
Duzgun 2008 0/50 17/50 48.9 % 0.03 [ 0.00, 0.46 ]
Faglia 1996a 3/36 11/34 31.6 % 0.26 [ 0.08, 0.84 ]
Subtotal (95% CI) 101 99 100.0 % 0.15 [ 0.06, 0.36 ]
Total events: 5 (HBOT), 35 (Control)
Heterogeneity: Chi2 = 2.94, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 4.33 (P = 0.000015)
Test for subgroup differences: Chi2 = 1.47, df = 1 (P = 0.23), I2 =32%
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Analysis 1.15. Comparison 1 Diabetic ulcers, Outcome 15 Minor amputations.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 15 Minor amputations
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abidia 2003 1/9 0/9 13.4 % 3.00 [ 0.14, 65.16 ]
Doctor 1992 4/15 2/15 26.1 % 2.00 [ 0.43, 9.32 ]
Duzgun 2008 4/50 24/50 32.1 % 0.17 [ 0.06, 0.45 ]
Londahl 2010 4/49 4/45 28.4 % 0.92 [ 0.24, 3.46 ]
Total (95% CI) 123 119 100.0 % 0.76 [ 0.19, 3.10 ]
Total events: 13 (HBOT), 30 (Control)
Heterogeneity: Tau2 = 1.34; Chi2 = 10.17, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Diabetic ulcers, Outcome 16 Minor amputations. Best-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 16 Minor amputations. Best-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abidia 2003 1/9 1/9 13.5 % 1.00 [ 0.07, 13.64 ]
Doctor 1992 4/15 2/15 24.3 % 2.00 [ 0.43, 9.32 ]
Duzgun 2008 4/50 24/50 32.5 % 0.17 [ 0.06, 0.45 ]
Londahl 2010 4/49 7/45 29.8 % 0.52 [ 0.16, 1.67 ]
Total (95% CI) 123 119 100.0 % 0.55 [ 0.17, 1.75 ]
Total events: 13 (HBOT), 34 (Control)
Heterogeneity: Tau2 = 0.83; Chi2 = 8.03, df = 3 (P = 0.05); I2 =63%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Diabetic ulcers, Outcome 17 Minor amputations. Worst-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 17 Minor amputations. Worst-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Abidia 2003 2/9 0/9 15.0 % 5.00 [ 0.27, 91.52 ]
Doctor 1992 4/15 2/15 25.7 % 2.00 [ 0.43, 9.32 ]
Duzgun 2008 4/50 24/50 30.8 % 0.17 [ 0.06, 0.45 ]
Londahl 2010 5/49 4/45 28.4 % 1.15 [ 0.33, 4.01 ]
Total (95% CI) 123 119 100.0 % 0.91 [ 0.21, 4.02 ]
Total events: 15 (HBOT), 30 (Control)
Heterogeneity: Tau2 = 1.61; Chi2 = 12.02, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Diabetic ulcers, Outcome 18 Transcutaneous oxygen tensions change after
treatment.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 18 Transcutaneous oxygen tensions change after treatment
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Faglia 1996a 35 14 (11.8) 33 5 (5.4) 100.0 % 9.00 [ 4.68, 13.32 ]
Total (95% CI) 35 33 100.0 % 9.00 [ 4.68, 13.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.08 (P = 0.000045)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Diabetic ulcers, Outcome 19 Absolute difference in transcutaneous oxygen at
end of treatment.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 19 Absolute difference in transcutaneous oxygen at end of treatment
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abidia 2003 8 49 (19) 8 47 (20) 10.1 % 2.00 [ -17.12, 21.12 ]
Faglia 1996a 35 37.3 (16.1) 33 26.3 (13.5) 74.5 % 11.00 [ 3.95, 18.05 ]
Lin 2001 17 57.7 (20.7) 12 35.82 (21.2) 15.4 % 21.88 [ 6.37, 37.39 ]
Total (95% CI) 60 53 100.0 % 11.76 [ 5.68, 17.84 ]
Heterogeneity: Chi2 = 2.68, df = 2 (P = 0.26); I2 =25%
Test for overall effect: Z = 3.79 (P = 0.00015)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Diabetic ulcers, Outcome 20 Ulcer area reduction (%).
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 20 Ulcer area reduction (%)
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kessler 2003 14 48.1 (30.3) 13 41.7 (27.3) 34.7 % 6.40 [ -15.33, 28.13 ]
Ma 2013 18 42.4 (20) 18 18.1 (6.5) 65.3 % 24.30 [ 14.58, 34.02 ]
Total (95% CI) 32 31 100.0 % 18.10 [ 1.40, 34.79 ]
Heterogeneity: Tau2 = 86.47; Chi2 = 2.17, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 Diabetic ulcers, Outcome 21 Quality of life - SF-36 physical summary score.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 21 Quality of life - SF-36 physical summary score
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Londahl 2010 23 31.9 (10.8) 10 32.1 (11.5) 100.0 % -0.20 [ -8.58, 8.18 ]
Total (95% CI) 23 10 100.0 % -0.20 [ -8.58, 8.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Diabetic ulcers, Outcome 22 Quality of life - SF-36 mental summary score.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 1 Diabetic ulcers
Outcome: 22 Quality of life - SF-36 mental summary score
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Londahl 2010 23 53.3 (11.8) 10 46.7 (15.1) 100.0 % 6.60 [ -3.93, 17.13 ]
Total (95% CI) 23 10 100.0 % 6.60 [ -3.93, 17.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Venous ulcers, Outcome 1 Healed at 18 weeks.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 2 Venous ulcers
Outcome: 1 Healed at 18 weeks
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hammarlund 1994 2/8 0/8 100.0 % 5.00 [ 0.28, 90.18 ]
Total (95% CI) 8 8 100.0 % 5.00 [ 0.28, 90.18 ]
Total events: 2 (HBOT), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Venous ulcers, Outcome 2 Healed at 18 weeks. Best-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 2 Venous ulcers
Outcome: 2 Healed at 18 weeks. Best-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hammarlund 1994 4/8 0/8 100.0 % 9.00 [ 0.56, 143.89 ]
Total (95% CI) 8 8 100.0 % 9.00 [ 0.56, 143.89 ]
Total events: 4 (HBOT), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Venous ulcers, Outcome 3 Healed at 18 weeks. Worst-case..
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 2 Venous ulcers
Outcome: 3 Healed at 18 weeks. Worst-case.
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hammarlund 1994 2/8 3/8 100.0 % 0.67 [ 0.15, 2.98 ]
Total (95% CI) 8 8 100.0 % 0.67 [ 0.15, 2.98 ]
Total events: 2 (HBOT), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Venous ulcers, Outcome 4 Wound size reduction at end treatment (6 weeks).
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 2 Venous ulcers
Outcome: 4 Wound size reduction at end treatment (6 weeks)
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hammarlund 1994 8 35.7 (17) 8 2.7 (11) 100.0 % 33.00 [ 18.97, 47.03 ]
Total (95% CI) 8 8 100.0 % 33.00 [ 18.97, 47.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Venous ulcers, Outcome 5 Wound size reduction at 18 weeks.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 2 Venous ulcers
Outcome: 5 Wound size reduction at 18 weeks
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hammarlund 1994 6 55.8 (43.1) 5 26.2 (45.3) 100.0 % 29.60 [ -22.99, 82.19 ]
Total (95% CI) 6 5 100.0 % 29.60 [ -22.99, 82.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Mixed ulcers types, Outcome 1 Healed at end of treatment (30 days).
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 3 Mixed ulcers types
Outcome: 1 Healed at end of treatment (30 days)
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaur 2012 3/15 0/15 100.0 % 7.00 [ 0.39, 124.83 ]
Total (95% CI) 15 15 100.0 % 7.00 [ 0.39, 124.83 ]
Total events: 3 (HBOT), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Mixed ulcers types, Outcome 2 Major amputations.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 3 Mixed ulcers types
Outcome: 2 Major amputations
Study or subgroup HBOT Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kaur 2012 1/15 5/15 100.0 % 0.20 [ 0.03, 1.51 ]
Total (95% CI) 15 15 100.0 % 0.20 [ 0.03, 1.51 ]
Total events: 1 (HBOT), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Mixed ulcers types, Outcome 3 Periwound transcutaneous oxygen tensions at
the end of treatment.
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 3 Mixed ulcers types
Outcome: 3 Periwound transcutaneous oxygen tensions at the end of treatment
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kaur 2012 15 34.3 (14.8) 15 21.4 (9.5) 100.0 % 12.90 [ 4.00, 21.80 ]
Total (95% CI) 15 15 100.0 % 12.90 [ 4.00, 21.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0045)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Mixed ulcers types, Outcome 4 Ulcer area reduction (%).
Review: Hyperbaric oxygen therapy for chronic wounds
Comparison: 3 Mixed ulcers types
Outcome: 4 Ulcer area reduction (%)
Study or subgroup HBOT Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kaur 2012 15 59.27 (36.59) 15 -2.61 (14.77) 100.0 % 61.88 [ 41.91, 81.85 ]
Total (95% CI) 15 15 100.0 % 61.88 [ 41.91, 81.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.07 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours [control] Favours [HBOT]
66Hyperbaric oxygen therapy for chronic wounds (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L T A B L E S
Table 1. Patients missing from final follow-up
Study Missing but included Missing total Per cent of entered
Khandelwal 2013 0 11 28%
Kaur 2012 0 0 0
Ma 2013 0 0 0
Doctor 1992 0 0 0
Faglia 1996a 0 2 3%
Lin 2001 0 0 0
Abidia 2003 0 2 11%
Hammarlund 1994 0 5 31%
Kessler 2003 0 1 <1%
Duzgun 2008 0 0 0
Londahl 2010 19 19 12% - included in ITT
Wang 2011 0 9 10%
ITT: intention-to-treat
A P P E N D I C E S
Appendix 1. Original search methods section 2003 and first update 2012
See: Cochrane Wounds Group search strategy.
Original review:
All publications potentially describing RCTs of therapeutic agents for chronic ulcers were sought from the Specialised Trials Register of
the Wounds Group. The Wounds Group Trials Register contains citations of trials identified from searches of 19 electronic databases,
including MEDLINE, and EMBASE, and through handsearching journals and conference proceedings.
The Cochrane Central Register of Controlled Trials (CENTRAL) was searched; MEDLINE (1966 to 2003) and EMBASE (1974 to
2003) were also searched.
In addition we made a systematic search for relevant controlled trials in specific hyperbaric literature sources:
1. Experts in the field and leading hyperbaric therapy centres (as identified by personal communication and searching the Internet)
were contacted and asked for additional relevant data in terms of published or unpublished randomised trials.
2. Relevant hyperbaric textbooks (Kindwall 1999; Jain 1999; Oriani 1996), journals (Undersea and Hyperbaric Medicine,
Hyperbaric Medicine Review, South Pacific Underwater Medicine Society (SPUMS) Journal, European Journal of Hyperbaric
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Medicine and Aviation, Space and Environmental Medicine Journal) and conference proceedings (Undersea and Hyperbaric Medical
Society, SPUMS, European Undersea and Baromedical Society, International Congress of Hyperbaric Medicine) published since
1980 were handsearched.
3. Authors of relevant studies were contacted to request details of unpublished or ongoing investigations.
4. Database of randomised controlled trials in hyperbaric medicine was searched (DORCTHIM, Bennett 2003). We used the
specific search terms “hyperbaric oxygenation”, “wounds and injuries”, “ulcer”, “skin ulcer”, “diabetic foot”, “varicose ulcer” and “foot
ulcer”.
First update searches:
The Cochrane Wounds Group Specialised Register (searched January 12 2012);
The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 4);
Ovid MEDLINE (1950 to January Week 1 2012);
Ovid MEDLINE (In-Process & Other Non-Indexed Citations, January 11, 2012);
Ovid EMBASE (1980 to 2012 Week 01);
EBSCO CINAHL (1982 to January 6 2012).
Appendix 2. Ovid MEDLINE search strategy
1 exp Chronic Disease/
2 exp Wound Healing/
3 and/1-2
4 exp Skin Ulcer/
5 exp Diabetic Foot/
6 (skin ulcer$ or foot ulcer$ or diabetic foot or varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or arterial ulcer$ or (lower
extremit$ adj ulcer$) or crural ulcer$ or ulcus cruris).ti,ab.
7 ((ischaemic or ischemic) adj (wound$ or ulcer$)).ti,ab.
8 (bed sore$ or pressure sore$ or pressure ulcer$ or decubitus ulcer$).ti,ab.
9 chronic wound$.ti,ab.
10 (chronic adj3 ulcer$).ti,ab.
11 or/3-10
12 exp Hyperbaric Oxygenation/
13 (hyperbar$ adj oxygen$).ti,ab.
14 high pressure oxygen$.ti,ab.
15 oxygen.ti.
16 or/12-15
Appendix 3. Ovid EMBASE search strategy
1 exp Chronic Wound/
2 exp Skin Ulcer/
3 exp Diabetic Foot/
4 (skin ulcer$ or foot ulcer$ or diabetic foot or varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or arterial ulcer$ or (lower
extremit$ adj ulcer$) or crural ulcer$ or ulcus cruris).ti,ab.
5 ((ischaemic or ischemic) adj (wound$ or ulcer$)).ti,ab.
6 (bed sore$ or pressure sore$ or pressure ulcer$ or decubitus ulcer$).ti,ab.
7 chronic wound$.ti,ab.
8 (chronic adj3 ulcer$).ti,ab.
9 or/1-8
10 exp hyperbaric oxygen/
11 (hyperbar$ adj oxygen$).ti,ab.
12 high pressure oxygen$.ti,ab.
13 oxygen.ti.
14 or/10-13
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15 9 and 14
Appendix 4. EBSCO CINAHL search strategy
S14 S8 and S13
S13 (S9 or S10 or S11 or S12)
S12 TI oxygen
S11 TI high pressure oxygen or AB high pressure oxygen
S10 TI hyperbar* oxygen* or AB hyperbar* oxygen*
S9 (MH “Hyperbaric Oxygenation”)
S8 S1 or S2 or S3 or S4 or S5 or S6 or S7
S7 TI ( chronic wound* or chronic ulcer* ) or AB ( chronic wound* or chronic ulcer* )
S6 TI ( bed sore* or pressure sore* or pressure ulcer* or decubitus ) or AB ( bed sore* or pressure sore* or pressure ulcer* or decubitus )
S5 AB skin ulcer* or foot ulcer* or diabetic foot* or diabetic feet or leg ulcer* or varicose ulcer* or venous ulcer* or stasis ulcer* or
arterial ulcer* or ischemic ulcer* or ischaemic ulcer* or lower extremit*
S4 TI skin ulcer* or foot ulcer* or diabetic foot* or diabetic feet or leg ulcer* or varicose ulcer* or venous ulcer* or stasis ulcer* or
arterial ulcer* or ischemic ulcer* or ischaemic ulcer* or lower extremit*
S3 (MH “Diabetic Foot”)
S2 (MH “Skin Ulcer+”)
S1 (MH “Wounds, Chronic”)
WH A T ’ S N E W
Last assessed as up-to-date: 18 February 2015.
Date Event Description
18 February 2015 New search has been performed Second update, new search, three trials added (Kaur
2012; Khandelwal 2013; Ma 2013). We created a
“mixed ulcers group” including trials with patients suf-
fered from diabetic and venous ulcers. “Risk of bias as-
sessment” and “Summary of findings” table completed
18 February 2015 New citation required but conclusions have not
changed
New author added to review team.
H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 2, 2004
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Date Event Description
12 January 2012 New search has been performed First update, new search, four trials added (Duzgun
2008; Kessler 2003; Londahl 2010; Wang 2011). ’Risk
of bias’ assessment and ’Summary of findings’ table
completed
12 January 2012 New citation required and conclusions have changed New author added to review team.
7 November 2008 Amended Converted to new review format.
14 October 2003 New citation required and conclusions have changed Substantive amendment.
C O N T R I B U T I O N S O F A U T H O R S
P. Kranke: initiated the study, dealt with correspondence, developed the protocol, undertook the searching and selected studies, appraised
and data abstracted studies, entered data and wrote the review and participated in the update of the review.
M. Bennett: developed and edited the protocol, undertook the searching and selected studies, appraised and data abstracted studies,
undertook the statistical analysis and wrote the review and the updated review.
M.Martyn-St James: appraised and data abstracted selected studies identified for the update, and undertook the statistical and narrative
synthesis for the update.
S. Debus: commented on the protocol and the review.
A. Schnabel: appraised and data abstracted studies, contributed to discussion.
S. Weibel: appraised and data abstracted selected studies, and undertook the statistical and narrative synthesis for the second update.
Contributions of editorial base:
Nicky Cullum: edited the review, advised on methodology, interpretation and review content. Approved the final review and review
update prior to submission.
Sally Bell-Syer: coordinated the editorial process. Advised on methodology, interpretation and content. Edited the review and the
updated reviews.
Ruth Foxlee: designed the search strategy, ran the searches and edited the search methods section for the update.
Amanda Briant: ran the searches for the second update.
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D E C L A R A T I O N S O F I N T E R E S T
Michael Bennett is a salaried hyperbaric physician working in a State-funded institution where he treats participants with chronic
wounds from a variety of causes. Part of his entitlement in that position is reimbursement for attendance at appropriate scientific
meetings.
The post held by Marrissa Martyn-St James was funded by the National Institute for Health Research (NIHR) under its Programme
Grants for Applied Research funding scheme (RP-PG-0407-10428). The views expressed in this review are those of the author(s) and
not necessarily those of the NHS, the NIHR or the Department of Health.
S O U R C E S O F S U P P O R T
Internal sources
• Departmental sources from the Department of Anaesthesiology, University of Wuerzburg, Germany, Germany.
External sources
• This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane
Wounds. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic
Reviews Programme, NIHR, NHS or the Department of Health, UK.
• NIHR Programme Grants for Applied Research, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this update, we identified one trial (Kaur 2012) which enrolled patients with different co-morbidities and therefore different types
of ulcers. Due to the possibility that in future more studies of this types will be found, we decided to add this as a new comparison
termed “mixed ulcers types” to the analysis.
We introduced some changes within the methodological quality assessment (performance bias). In the original review, we defined
“unclear risk of bias” for “blinding of participants and personnel”, when the study does not specify the blinding process independent
of the described treatment of the control group (e.g. no sham therapy offered) . We reconsidered this point and judged to assess studies
as “high risk of bias”, when they offered no sham therapy to the patients of the control arm. Therefore, Doctor 1992; Duzgun 2008;
Faglia 1996a; Kessler 2003 are now assessed as “high risk of performance bias”.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Wound Healing; Amputation [utilization]; Chronic Disease; Diabetic Foot [∗therapy]; Hyperbaric Oxygenation [adverse effects];
Randomized Controlled Trials as Topic; Varicose Ulcer [∗therapy]
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MeSH check words
Humans
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